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 1.1. TABLETS: 
 1.1.1. Definition:                                                
          (Lachman L., et al., 1991) 
            Tablets are tamper proof solid unit dosage forms containing medicament or 
mixture of medicaments and excipients compressed or moulded into solid cylindrical 
shape having either flat or convex surfaces.  
1.1.2. Properties of tablets:  
The attributes of an acceptable tablet are as follows: 
 The tablet must be sufficiently strong and resistant to shock, abrasion, should 
withstand handling during manufacturing, packing, shipping, and use. 
Hardness and friability tests measure this property. 
 Tablet must be uniform in weight and in drug content of the individual tablet. 
This is measured by the weight variation and content uniformity tests. 
 The drug content of the tablet must be bioavailable. This property is measured 
by the dissolution test. Accurate bioavailability can be obtained from the drug 
levels in the blood after its administration. 
 Tablets must be elegant in appearance, characteristic shape, colour and other 
markings necessary to identify the product. 
 Tablets must retain all these functional attributes which include drug stability 
andefficacy.
1. INTRODUCTION 
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1.2. ADVANTAGES AND DISADVANTAGES: 
1.2.1. Advantages: 
 Offers greatest capability of all oral dosage forms for the greatest dosage 
precision & least content Unifo.   
 High patient compliance. 
 Their cost is lowest of all dosage forms 
 One of the major advantages of tablet over capsules is that the tablet is 
essentially “tamper proof dosage form”. 
 Easiest and cheapest to packaging and shipment 
 They are having best combined properties of chemical, mechanical and 
microbiological properties 
 Accuracy of dose is maintained since tablet is a solid unit dosage forms 
 Longer expiry period and minimum microbial spillage owing to lower 
moisture content 
 Large scale manufacturing is feasible in comparison to other dosage forms. 
Therefore, economy can be achieved. 
 Organoleptic properties (colour taste, appearance, and odour) are improved by 
coating of the tablets. Product identification is easy and marketing done with 
the help of grooved punches and printing with edible ink. 
 As a tablet is not a sterile dosage form, stringent environmental conditions are 
not required in the tablet department.       
 
1.2.2. Disadvantages:     
 Some drugs resist compression owing to their amorphous nature & low 
density character. 
 Drugs with poor wetting, slow dissolution property, large dosages or any 
combination of these features may be difficult or impossible to formulate & 
manufacture as a tablet. 
 A major disadvantage of capsules over tablets is their higher cost. 
 It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
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 Slow onset of action as compared to parenterals, liquid orals and capsules. 
 The amount of liquid drug (e.g., vitamin E, Simethicone) that can be trapped 
into a tablet is very less. 
 Difficult to swallow for kids, terminally ill and geriatric patients. 
     Patients undergoing radiotherapy cannot swallow tablet. 
  
1.3. TYPES AND CLASSES OF TABLETS:                                              
  (Lachman  L., et al., 1991)                                                                     
  Tablets are classified by their route of administration or function, by the type 
of drug delivery system they represent within that route, by their form and method of 
manufacture. 
Tablets ingested orally 
      1. Compressed tablets (CT) 
      2. Multiple compressed tablets (MCT) 
         3.          Layered tablets and Bi-layer tablets 
     4.            Compression coated tablets  
      5. Repeat action tablets 
      6. Delayed action and enteric coated tablets 
      7. Sugar and chocolate coated tablets 
      8. Film coated tablets 
      9. Air suspension coated tablets 
      10. Chewable tablets 
      11.         Dispersible tablets 
 Tablets used in oral cavity        
      1.       Buccal tablet 
      2.       Sublingual tablets 
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      3.      Troches, Lozenges and dental cones 
 Tablets used to prepare solution 
             1. Effervescent tablets 
      2. Dispensing tablets (DT) 
      3. Hypodermic tablets (HT) 
      4. Tablet triturates (TT) 
 
        The goal of any drug delivery system is to provide a therapeutic amount of 
drug in the proper site in the body to achieve promptly and then to maintain the 
desired   drug concentration that is, the drug delivery system should delivery system 
should deliver drug at a rate dedicated by the needs of the body over a specified 
period of treatment    
1.4. ORAL DRUG DELIVERY:                                           
 (Swarbrick  James., 2007) 
            This is the most widely utilized route of administration among all the routes 
that have been explored for systemic delivery of drugs via pharmaceutical products of 
different dosage form. Oral route is considered most natural, uncomplicated, 
convenient and safe due to its ease of administration, patient acceptance and cost 
effective manufacturing process. 
       For many drug substances conventional immediate release formulations 
provide clinically effective therapy while maintaining the required balance of  
pharmacokinetic and pharmacodynamics profiles with an acceptable level of safety to 
the patient. 
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         Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
and development of new drug entities, pharmaceutical formulations, mainly because 
of patient acceptance and convenience in administration.  
         Oral route of drug administration have wide acceptance up to 50-60% of 
total dosage forms. Solid dosage forms are popular because of ease of administration, 
accurate dosage, self-medication, pain avoidance and most importantly patient 
compliance. The most popular solid dosage forms are tablets and capsules. But the 
important drawback of these dosage forms is the difficulty to swallow.  
        Oral dosage form is the most popular route for drug therapy. Over 80% of the 
drugs formulated to produce systemic effects in the United States are produced as oral 
dosage forms. Compared to other oral dosage forms, tablets are the manufacturer’s 
dosage form of choice because of their relatively low cost of manufacture, package. 
1.4.1. Current technologies in oral drug delivery:  
(Brahmankar D.M. and Jaiswal   S.B.,2009; Robinson J.R. and Lee V.H.L., 2009) 
                     Over the last 3 decades, many novel oral drug therapeutic systems have 
been invented along with the appreciable development of drug delivery technology. 
Although these advanced drug delivery system are manufactured or fabricated in 
traditional pharmaceutical formulations, such as Tablets, Capsules, Sachets, 
Suspensions, Emulsions, and Solutions, they are superior to the conventional oral 
dosage forms in terms of their therapeutic efficacies, toxicities, and stabilities.  
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         Based on the desired therapeutic objectives, oral drug delivery system may 
be assorted into three categories:  
• Immediate-release preparations,  
• Controlled-release preparations and                                                                                                                                                 
•     Targeted- release preparations.  
 
 1.4.1.1. Immediate-Release Preparations:                    
   ( Syed  Azeem., et al., 2011) 
              These preparations are primarily intended to achieve faster onset of action for 
drugs such as analgesics, antipyretics, and coronary vasodilators. Other advantages 
include enhanced oral bioavailability through transmucosal delivery and pre gastric 
absorption, convenience in drug administration to dysphasic patients, especially the 
elderly and bedridden, and new business opportunities.  
         Conventional IR formulations include fast disintegrating tablets and granules 
that use effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and 
citric acid (or tartaric acid), and superdisintegrants, such as Sodium starch glycolate, 
Croscarmellose sodium, and Crospovidone. Current technologies in fast-dispersing 
dosage forms include modified tableting systems, floss or Shear form technology, 
which employs application of centrifugal force and controlled temperature, and 
freeze-drying.  
 1.4.1.2. Controlled-Release Preparations:                  
 (Robinson J.R. and Lee V.H.L., 2009) 
                 The currently employed CR technologies for oral drug delivery are 
diffusion-controlled systems; solvent activated systems, and chemically controlled 
systems. Diffusion-controlled systems include monolithic and reservoir devices in 
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which diffusion of the drug is the rate-limiting step, respectively, through a polymer 
matrix or a polymeric membrane. Solvent-activated systems may be either 
Osmotically controlled or controlled by polymer swelling. Chemically controlled 
systems release drugs via polymeric degradation (surface or bulk matrix erosion) or 
cleavage of drug from a polymer chain. It is worth mentioning here that the so-called 
programmed-release (‘‘tailored-release’’) profile of a final control release product is 
rarely the outcome of a single pharmaceutical principle. Depending on the specific 
physicochemical properties of the drug in question and desired therapeutic objectives, 
different formulation and control release principles may be proportionally combined 
within the same dosage form. This task appears to be simpler when realized in terms 
of appropriate selection of polymers and excipients that incorporate desired 
principles. 
 1.4.1.3. Targeted-Release Preparations:       
                  Site-specific oral drug delivery requires spatial placement of a drug 
delivery device at a desired site within the GI tract. Although it is virtually possible to 
localize a device within each part of GI tract, the attainment of site-specific delivery 
in the oral cavity and the rectum is relatively easier than in the stomach and the small  
and large intestines. The latter requires consideration of both longitudinal and 
transverse aspects of GI constraints.  
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1.5. MANUFACTURING METHODS OF TABLETS:                                 
  (Rowley F.A., 2005)   
 
There are four general methods of tablet preparation. 
 Direct compression                                                                                                                             
 Wet granulation method 
 Dry granulation method 
 Fluidized bed granulation 
                  In the tablet-pressing process, it is important that all ingredients be 
dry, powdered, and of uniform grain size as much as possible. The main guideline in 
manufacture is to ensure that the appropriate amount of active ingredient is equal in 
each tablet so ingredients should be well-mixed. Compressed tablets are exerted to 
great pressure in order to compact the material. If a sufficiently homogenous mix of 
the components cannot be obtained with simple mixing, the ingredients must be 
granulated prior to compression to assure an even distribution of the active compound 
in the final tablet. Two basic techniques are used to prepare powders for granulation 
into a tablet: wet granulation and dry granulation. Powders that can be mixed well do 
not require granulation and can be compressed into tablets through direct 
compression.  
1.5.1. Direct Compression: 
    This method is used when a group of ingredients can be blended and placed 
in a tablet press to make a tablet without any of the ingredients having to be changed. 
This is not very common because many tablets have active pharmaceutical ingredients 
which will not allow for direct compression due to their concentration or the 
excipients used in formulation are not conducive to direct compression. 
Tenofovir Disoproxil fumarate immediate release tablets Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 9 
 
    Granulation is the process of collecting particles together by creating bonds 
between them. There are several different methods of granulation. The most popular, 
which is used by over 70% of formulation in tablet manufacture is wet granulation. 
Dry granulation is another method used to form granules. 
 
 1.5.2. Wet granulation:   
 
               Wet granulation is a process of using a liquid binder or adhesive to the 
powder mixture. The amount of liquid can be properly managed, and over wetting 
will cause the granules to be too hard and under wetting will cause them to be too soft 
and friable. Aqueous solutions have the advantage of being safer to deal with than 
solvents. 
1.5.2.1. Procedure of Wet Granulation: 
 
Step 1: Weighing and Blending - the active ingredient, filler, disintegration agents, 
are weighed and mixed. 
Step 2: The wet granulate is prepared by adding the liquid binder/adhesive. Examples 
of binders/adhesives include aqueous preparations of cornstarch, natural gums such as 
acacia and cellulose derivatives such as methyl cellulose, CMC, gelatin, and 
povidone. Ingredients are placed within a granulator which helps ensure correct 
density of the composition. 
Step 3: Screening the damp mass into pellets or granules 
Step 4: Drying the granulation 
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Step 5: Dry screening: After the granules are dried, pass through a screen of smaller 
size than the one used for the wet mass to select granules of uniform size to allow 
even fill in the die cavity 
Step 6: Lubrication- A dry lubricant, anti adherent and glidant are added to the 
granules either by dusting over the spread-out granules or by blending with the 
granules. It reduces friction between the tablet and the walls of the die cavity. Anti 
adherent reduces sticking of the tablet to the die and punch. 
Step7: liquid binder, but sometimes many actives are not compatible with water. 
Water mixed into the powder can form bonds between powder particles that are 
strong enough to lock them in together. However, once the water dries, the powders 
may fall apart and therefore might not be strong enough to create and hold a bond.  
1.5.3. Dry granulation: 
 
             This process is used when the product needed to be granulated may be 
sensitive to moisture and heat. Dry granulation can be conducted on a press using 
slugging tooling or on a roller compactor commonly referred to as a chilsonator. Dry 
granulation equipment offers a wide range of pressure and roll types to attain proper 
densification. However, the process may require repeated compaction steps to attain 
the proper granule end point. It requires drugs or excipients with cohesive properties. 
• Some granular chemicals are suitable for direct compression (free flowing) 
e.g. potassium chloride. 
• Tableting excipients with good flow characteristics and compressibility allow 
for direct compression of a variety of drugs. 
 
Tenofovir Disoproxil fumarate immediate release tablets Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 11 
 
1.5.3.1. Two main dry granulation processes:  
 Slugging process: 
                Granulation by Slugging is the process of compressing dry powder of tablet 
formulation with tablet press having die cavity large enough in diameter to fill 
quickly. The accuracy or condition of Slug is not too important. Only sufficient 
pressure to compact the powder into uniform slugs should be used. Once slugs are 
produced they are reduced to appropriate granule size for final compression by 
screening and milling. 
 Roller compaction: 
              The compaction of powder by means of pressure roll can also be 
accomplished by a machine called Chilsonator. Unlike tablet machine, the Chilsonator 
turns out a compacted mass in a steady continuous flow. The powder is fed down 
between the rollers from the hopper which contains a spiral auger to feed the powder 
into the compaction zone. Like slugs, the aggregates are screened or milled for 
production into granules.  
 1.5.4. Fluidized bed granulation: 
 
              It is a multiple step process performed in the same vessel to pre-heat, 
granulate and dry the powders. It is today a commonly used method in 
pharmaceuticals because it allows the individual company to more fully controls the 
powder preparation process. It requires only one piece of machinery that mixes all the 
powders and granules on a bed of air. 
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1.6. EXCIPIENTS USED IN TABLET:                          
( Aulton M .E., 2002)  
              Excipients are inert substances used as diluents or vehicles for a drug. In the 
pharmaceutical industry it is a catch all terms which includes various sub-groups. 
Comprising diluents or fillers, binders or adhesives, disintegrants, lubricants, glidants 
or flavours, fragrances and sweeteners.    
   All of these must meet certain criteria as follows:- 
 They must be physiological inert. 
 They must be acceptable to regulatory agencies 
 They must be physiologically and chemically stable. 
 They must be free of any bacteria considered to be pathogenic or otherwise    
objectionable. 
 They must be not interfere with the bioavailability of the drug. 
 They must be commercially available in the form and purity commensurate to 
pharmaceutical standards. 
 Cost must be relatively inexpensive 
               To assure that no excipient interferences with the utilization of the drug, the 
formulator must carefully and critically evaluate combinations of the drug with each 
of the contemplated excipients and must ascertain compliance of each ingredient with 
existing standards and regulations. 
     The screening of drug-excipients and excipient-excipient interactions should 
be carried out routinely in preformulation studies. 
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1.6.1. Fillers (Diluents): 
           Tablet fillers of comprise a heterogeneous group of substances. Since they 
often comprise the bulk of the tablet, selection of a candidate from this group as a 
carrier for a drug is of prime importance.  
1.6.2. Binders: 
    Binders are the glue that holds powders together to form granules. They are 
the adhesives that are added to tablet formulations to provide the cohesiveness 
required for that bonding together of the granules under compaction to form a tablet. 
The quantity used and the method of application must be carefully regulated, since the 
tablet must remain intact when swallowed and then release its medicament. 
 Natural polymers such as Starches or Gums include acacia, Tracaganth 
and Gelatin. 
 Synthetic polymers such as polyvinyl pyrrolidine, Methyl and Ethyl 
cellulose and Hydroxyl propyl cellulose. Commonly used binders are 
Gelatin, Glucose, Methylcellulose, Acacia, Starch paste, Povidone, 
Alcohol, PVP in water, PVP in alcohol and Sorbitol in water. 
1.6.3. Lubricants: 
        Lubricants are used in tablet formulation to ease the ejection of the tablet 
from the die, to prevent sticking of tablets to the punches, and to prevent excessive 
Wear on punches and dies. They function by interposing a film of low shear strength 
at the interface between the tablet and the die wall and the punch face. 
In selecting a lubricant, the following should be considered: 
 Lubricants markedly reduce the bonding properties of many excipients.  
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 Over blending is one of the main causes of lubrication problems. Lubricants 
should be added last to the granulation and tumble-blended for not more than 
10 min. 
 Lubricant efficiency is a function of particle size; therefore, the finest grade 
available should be used and screened through a 100-300 mesh screen before 
use. 
Examples of lubricants commonly used are magnesium Stearic acid, talc, starch, 
Magnesium stearate. 
1.6.4. Disintgrents: 
   Disintegrate are used in tablet preparation to break the tablet faster. But some 
of the disintegrants are also having property of enhancing solubility of insoluble drug. 
Examples 
 Crospovidone: Crospovidone is disintegrant, Crospovidone also 
enhances solubility. 
 Sodium starch glycollate: Sodium starch glycollate is widely used in 
oral pharmaceuticals and as a disintegrant in capsule. 
1.6.5. Glidants:   
        Glidants are materials that improve the flow characteristics of granules by 
reducing the inter particulate friction. In proper amounts they also serve to assure 
smooth and uniform flow at all times. Many of the excipients commonly used in 
tablet formulations are especially applicable for use in chewable tablets due to their 
ability to provide the necessary properties of sweetness and chewability. In general; 
these fall into the sugar category, although a combination of excipients with artificial 
sweeteners may provide a satisfactory alternative. 
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1.6.6. Miscellaneous: 
1.6.6.1. Wetting Agents: 
         Wetting agents in tablet formulation aid water uptake and thereby 
enhancing disintegration and assisting in drug dissolution. Incorporation of anionic 
surfactant like Sodium Lauryl Sulphate (SLS) is known to enchance the dissolution. It 
has been established that SLS improves permeation of drug through biological 
membrane since it destroys the path through which drug has to pass and thus 
minimizing the path length for the drug to travel. Wetting agents are mainly added 
when hydrophobic drug is to be formulated into tablet. SLS, Sodium disobutyl sulfo 
succinate are used as wetting agent in tablet formulation. 
1.6.6.2. Dissolution Retardants: 
             Dissolution Retardants are incorporated into tablet formulation only when 
controlled release of drug is required. Waxy materials like Stearic acid and their esters 
can be used as dissolution retardants. 
1.6.6.3. Dissolution Enhancers: 
              They are the agents that alter the molecular forces between ingredients to 
enhance the dissolution of solute in the solvent. Fructose, Povidone, Surfactants are 
used as dissolution enhancer. 
1.6.6.4. Adsorbents: 
                     Adsorbents are the agents that can retain large quantities of liquids. 
Therefore liquids like Vitamin E can be incorporated into tablets by addition of 
adsorbents. Most commonly used adsorbents in pharmaceuticals are anhydrous 
Calcium phosphate, Starch, Magnesium carbonate, Bentonite, Kaolin, Magnesium 
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oxide. Generally the liquid to be adsorbed is first mixed with the adsorbent prior to 
incorporation into the formulation. 
1.6.6.5. Buffers: 
               Buffers are added to maintain a required pH since a change in pH may cause 
significant alteration in stability. Most commonly used buffering agent in tablet 
formulation includes sodium bicarbonate, calcium carbonate, and sodium citrate. 
1.6.6.6. Antioxidants: 
               Antioxidants are added in tablet formulation to protect drug from 
undergoing oxidation. Antioxidants undergo oxidation in place of drug or they block 
the oxidation reaction or they act as synergists to other antioxidants. 
1.6.6.7. Chelating Agents: 
                Chelating agents tend to form complexes with trace amount of heavy metals 
ions inactivating their catalytic activity in the oxidation of medicaments. 
Ethylenediamine tetra acetic acid and its salts, Dihydroxy ethyl glycerine, Citric acid 
and Tartaric acid are most commonly used chelators. 
1.6.6.8. Flavours: 
              Flavours are added to tablet formulation in order to make them enough in 
case of chewable tablet by improving the taste. Flavours are commonly used to 
improve the taste of chewable tablets as well as mouth dissolved tablets. Flavours are 
incorporated either as solids (spray dried flavours) or oils or aqueous (water soluble) 
flavours. 
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1.6.6.9. Sweeteners: 
             Sweeteners are added to tablet formulation to improve the taste of chewable 
tablets. Sweeteners used in tablet formulation- Mannitol, Lactose, Sucrose, Dextrose, 
Saccharin, Cyclamate, Aspartamine etc.       
1.7. TABLET COATING:                         
 (Anand Shah., et al.,2009) 
             Coated tablets are defined as the covered with one/more layers of mixtures of 
various substances such as natural waxes authorized colouring materials. Coating may 
also contain active ingredient. Substances used for coating are usually applied as 
solution/suspension under condition where vehicle evaporates.  
 Why Tablet Coating is required?  
A number of reasons can be suggested:  
 The core contains a material which has a bitter taste in the mouth or has an 
unpleasant odour.  
 Coating will protect the drug from the surroundings with a view to improve its 
stability.  
 Coating will increase the ease by which a tablet can be ingested by the patient.  
 Coating will develop the mechanical integrity; means coated products are 
more   resistant to mishandling (abrasion, attrition etc.)  
 The core contains a substance which is incompatible in the presence of light 
and subject to atmospheric oxidation, i.e. a coating is added to improve 
stability.  
 The core alone is inelegant.  
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 The active substance is coloured and migrates easily to stain hands and 
clothes.  
 The coated tablets are packed on high-speed packaging machine. Coating 
reduces friction and increases packaging rate.  
 Coating can modify the drug release profile, e.g., enteric coating, osmotic 
pump, pulsatile delivery.  
1.7.1. Types of coating: 
There are several types coatings are available, they are: 
• Sugar coating 
• Film coating 
• Enteric coating  
• Controlled release coating 
• Specialized coating 
• Compressed coating 
• Electrostatic coating 
• Dip coating 
• Vacuum film coating 
1.7.1.1. FILM COATING:                                    
      (Anand Shah., et al., 2009)  
                   Film coating is the process whereby a tablet, capsule, or pellet is 
surrounded by a thin layer of polymeric material. Film coated tablets are compressed 
tablets with a thin layer of suitable polymer capable of forming a skin like film over 
the tablet. The polymeric substance most commonly used are Hydroxy propyl methyl  
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cellulose, Hydroxy methyl cellulose. The film is usually coloured and has the 
advantage over sugar coating in that it is more durable, less bulky, and less time 
consuming to apply. The film coating protects the medicament from the atmospheric 
effects. By its composition the coating is designed to rupture & expose the core tablet 
at the desired location with in GIT. 
Reasons for film coating include: 
Appearance To change the colour, for branding purposes or other 
aesthetic reasons 
Stability To protect the active ingredient from moisture, light, and/or the acidic environment of the stomach 
Taste/odour  Masking To provide an easy to swallow tablet without the bitter taste 
of many actives 
Release characteristics Many film coating materials have functional properties 
which enable the delayed (enteric) release of dosage forms 
 
1.7.1.2. Process Description: 
                 Film coating is a deposition of a thin layer of polymer surrounding the 
tablet core .Conventional pan equipments may be used but now adays more 
sophisticated equipments are employed to have high degree of automation of coating 
time. The polymer is solubilised into solvent, other additives like plasticizer 
&pigments are added. Resulting solution is sprayed on to a rotated tablet bed. The 
drying conditions cause removal of the solvent, giving thin deposition material around 
each tablet.  
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1.7.1.3. Process Details: 
                Usually spray process is employed in preparation of film coated tablet. 
Accelacota is the type of prototype of perforated cylindrical drum providing drying air 
capacity. Fluidized bed equipment has made considerable impact where tablets are 
moving in a stream of air passing through the perforated bottom of a cylindrical 
column with a smaller cylindrical insert the stream of cores is rising in the centre of 
device together with spray mist applied in the middle of the bottom. For fluidized 
coating very hard tablet hardness above 20 N have to be used. 
1.7.1.4. Materials used in film coating:
 Opaquent extenders,   
 Miscellaneous coating solution components
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1.7.1.5. Used film formers: 
Hydroxy propyl methyl cellulose (HPMC),Methyl hydroxyl ethyl 
cellulose (MHEC),Ethyl cellulose (EC),Hydroxy propyl cellulose (HPC), 
sodium carboxy methyl cellulose (CMC), Acrylate polymers, Povidone. 
1.7.1.6. Advantages: 
 
 It is less time consuming technology. 
 Not much labour is required. 
 No adverse effect on disintegration time of tablet.  
 Production cost is low because material used for coating is cheap. 
 Protects drug from atmospheric changes such as light, air, moist. Resist 
cracking, Chipping. 
1.8. MECHANISM OF TABLET DISINTEGRATION:   
 ( Shangraw R F., et  al., 1980) 
                 Disintegrants, an important excipient of the tablet formulation, are always 
added to tablet to induce breakup of tablet when it comes in contact with aqueous 
fluid and this process of desegregation of constituent particles before the drug 
dissolution occurs, is known as disintegration process and excipients which induce 
this process are known as disintegrants. 
The tablet breaks to primary particles by one or more of the mechanisms: 
 capillary action (Wicking) 
 swelling 
 Due to deformation 
 Due to release of gases 
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1.8.1. Capillary action (Wicking): 
 
              Effective disintegrants that do not swell are believed to impart their 
disintegrating action through porosity and capillary action. Tablet porosity provides 
way for the penetration of fluid into tablets. The disintegrant particles (with 
cohesiveness and compressibility) themselves act to enhance porosity and provide 
these capillaries into the tablet. Liquid is drawn up or leak into these ways by 
capillary action and rupture the inter-particulate bonds causing the tablet to break into 
small particle. 
1.8.2. Swelling: 
 
              Not all disintegrants swell in contact with water swelling is believed to be a 
mechanism in which certain disintegrating agents (like starch) impart their 
disintegrating effect. By swelling on contact with water the adhesiveness of other 
ingredients in a tablet is overcome causing the tablet to disintegrate. 
 
        Figure1. 2 &1. 3: Mechanism of tablet disintegration by wicking and  
         Swelling: 
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Particles swell and break up the matrix from within; swelling sets up; localized stress 
spreads throughout the matrix. Water is pulled into pores by disintegrants and reduces 
the physical bonding between particles. 
1.8.3. Due to deformation:  
                                                                                                                                                                      
Starch grains are generally thought to be “elastic” in nature that is the grains that are 
deformed under pressure will return to their original shape when that pressure is 
removed. But, with the compression force involved in tableting, these grains are 
permanently deformed and are said to be “Energy Rich” with these energy being 
released upon exposure to water, i.e. the ability for starch to swell is higher in 
“Energy Rich starch” grains than in starch grains that have not been deformed under 
pressure. It is believed that no single mechanism is responsible for the action of most 
disintegrants. But rather, it is more likely the result of inter-relationships between 
these major mechanisms particles swell to pre compression size and break up the 
matrix 
                    
  Figure 1. 4: Mechanism of tablet disintegration by deformation 
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1.8.4. Due to release of gases: 
         Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due 
to generation of pressure within the tablet. This effervescent mixture is used when we 
needs to formulate very rapidly dissolving tablets or fast disintegrating tablet.                   
        
1.9. INTRODUCTION TO AIDS/HIV:      
 (http://www.en.wikipedia.org/wiki/HIV) 
 
               HIV (Human Immunodeficiency Virus) infection has now spread to every 
country in the world. Approximately 40 million people are currently living with HIV 
infection, and an estimated 25 million have died from this disease. The scourge of 
HIV has been particularly devastating in sub-Saharan Africa, but infection rates in 
other countries remain high. In the United States, approximately 1 million people are 
currently infected. Here are a few key points about the disease: 
 Globally, 85% of HIV transmission is heterosexual. 
 In the United States, approximately one-third of new diagnoses appear to be 
related to heterosexual transmission. Male-to-male sexual contact still 
accounts for approximately half of new diagnoses in the U.S. Intravenous drug 
use contributes to the remaining cases. Because the diagnosis may occur years 
after infection, it is likely that a higher proportion of recent infections are due 
to heterosexual transmission. 
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 Infections in women are increasing. Worldwide, 42% of people with HIV are 
women. In the United States, approximately 25% of new diagnoses are in 
women, and the proportion is rising. 
 There is good news on one front. New HIV infections in U.S. children have 
fallen dramatically. This is largely a result of testing and treating infected 
mothers, as well as establishing uniform testing guidelines for blood products.  
In order to understand HIV and AIDS, it is important to understand the 
meanings behind these terms: 
                 HIV stands for the human immunodeficiency virus. It is one of a group of 
viruses known as retroviruses. After getting into the body, the virus kills or damages 
cells of the body's immune system. The body tries to keep up by making new cells or 
trying to contain the virus, but eventually the HIV wins out and progressively destroys 
the body's ability to fight infections and certain cancers. 
                 AIDS stands for the Acquired Immuno Deficiency Syndrome. It is caused 
by HIV and occurs when the virus has destroyed so much of the body's defences that 
immune-cell counts fall to critical levels or certain life-threatening infections or 
cancers develop.  
1.9.1. HIV/AIDS Transmission: 
 HIV is transmitted when the virus enters the body, usually by injecting 
infected cells or semen. There are several possible ways in which the virus can 
enter. 
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 Most commonly, HIV infection is spread by having sex with an infected 
partner. The virus can enter the body through the lining of the vagina, vulva, 
penis, rectum, or mouth during sex. 
 HIV frequently spreads among injection-drug users who share needles or 
syringes that are contaminated with blood from an infected person. 
 Women can transmit HIV to their babies during pregnancy or birth, when 
infected maternal cells enter the baby's circulation. 
 HIV can be spread in health-care settings through accidental needle sticks or 
contact with contaminated fluids. 
 Very rarely, HIV spreads through transfusion of contaminated blood or blood 
components. Blood products are now tested to minimize this risk. If tissues or 
organs from an infected person are transplanted, the recipient may acquire 
HIV. Donors are now tested for HIV to minimize this risk. 
 People who already have a sexually transmitted disease, such as syphilis, 
genital herpes, chlamydial infection, gonorrhoea, or bacterial vaginosis, are 
more likely to acquire HIV infection during sex with an infected partner.  
 The virus does not spread through casual contact such as preparing food, 
sharing towels and bedding, or via swimming pools, telephones, or toilet seats. 
The virus is also unlikely to be spread by contact with saliva, unless it is 
contaminated with blood.                                                                                                                             
1.9.2. Structure of HIV:  
            The two copies of the viral RNA are protected by a protein coat and enclosed 
in a capsule. Also contained in the capsule are reverse transcriptase enzymes (which 
convert the single-stranded RNAs into double-stranded DNA copies), integrase 
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(which inserts the DNA version into the host genome), and protease (which cuts the 
long chain of polypeptides produced by viral RNA into individual enzyme 
components as new virus particles are budding off a cell membrane). The capsule is 
itself enclosed in a bilayer membrane obtained from the previous host cell; in the 
membrane are mounted P17 (the remains of a protein involved in budding off) and 
GP120 (the glycoprotein that binds the helper T-cell receptor and so enables the virus 
to gain entry into its host). 
 
Figure 1.5: Structure of HIV  
 
1.9.3. HIV/AIDS Symptoms and Signs: 
Many people with HIV do not know they are infected. 
 Many people do not develop symptoms after they first get infected with HIV. 
Others have a flu-like illness within several days to weeks after exposure to 
the virus. They complain of fever, headache, tiredness, and enlarged lymph 
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nodes in the neck. These symptoms usually disappear on their own within a 
few weeks. After that, the person feels normal and has no symptoms. This 
asymptomatic phase often lasts for years. 
 The progression of disease varies widely among individuals. This state may 
last from a few months to more than 10 years. 
 During this period, the virus continues to multiply actively and infects and 
kills the cells of the immune system. 
 The virus destroys the cells that are the primary infection fighters, a type of 
white blood cell called CD4 cells. 
 Even though the person has no symptoms, he or she is contagious and can pass 
HIV to others through the routes listed above. 
AIDS is the later stage of HIV infection, when the body begins losing its 
ability to fight infections. Once the CD4 cell count falls low enough, an 
infected person is said to have AIDS. Sometimes, the diagnosis of AIDS is 
made because the person has unusual infections or cancers that show the weak 
immune system. 
 The infections that happen with AIDS are called opportunistic infections 
because they take advantage of the opportunity to infect a weakened host. The 
infections include (but are not limited to)Pneumonia caused by Pneumocystis, 
which causes wheezing; Brain infection with toxoplasmosis which can cause 
trouble thinking or symptoms that mimic a stroke; Widespread infection with 
a bacteria called MAC (mycobacterium avium complex) which can cause 
fever and weight loss; Yeast infection of the swallowing tube (esophagus) 
which causes pain with swallowing; Widespread diseases with certain fungi 
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problems. 
 
 A weakened immune system can also lead to other unusual conditions:
• Lymphoma in (a fo
which can cause fever and trouble thinking;
• A cancer of the soft tissues called Kaposi's sarcoma, which causes 
brown, reddish, or purple spots that develop on the skin or in the 
mouth. 
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1.9.4. HIV/AIDS Diagnosis: 
   HIV infection is commonly diagnosed by blood tests. There are three main 
types of tests that are commonly used: (1) antibody tests, (2) RNA tests, and (3) a 
combination test that detects both antibodies and a piece of the virus called the p24  
protein. In addition, a blood test known as a Western blot is used to confirm the 
diagnosis. 
 Testing for HIV is usually a two-step process. First, an inexpensive screening 
test is done. If that test is positive, a second test (Western blot) is done to confirm the 
result. Antibody tests are the most common initial screening test used. There are 
different types of antibody screening tests available: 
 Most commonly, blood is drawn for an enzyme immunoassay (EIA). The test 
is usually run in a local laboratory, so results can take one to three days to 
come back. 
 Other tests can detect antibodies in body fluids other than blood such as saliva, 
urine, and vaginal secretions. Some of these are designed to be rapid tests that 
produce results in approximately 20 minutes. These tests have accuracy rates 
similar to traditional blood tests. 
 HIV home-testing kits are available at many local drug stores. Blood is 
obtained by a finger prick and blotted on a filter strip. Other test kits use saliva 
or urine. The filter strip is mailed in a protective envelope to a laboratory to be 
tested. Results are returned by mail in one to two weeks. 
              All positive antibody screening tests must be confirmed with a follow-up 
blood test called the Western blot to make a positive diagnosis. If the antibody test 
and the Western blot are both positive, the likelihood of a person being HIV infected 
is >99%. Sometimes, the Western blot is "indeterminate," meaning that it is neither 
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positive nor negative. In these cases, the tests are usually repeated at a later date. In 
addition, an RNA test for the virus might be done.   
Other tests, such as those that look for virus RNA and the combination tests are not 
commonly used for screening. 
1.9.5. Treatment:            
            Current treatment for HIV infection of highly active antiretroviral therapy, or 
HAART. This has been highly beneficial to many HIV-infected individuals since its 
introduction in 1996, when the protease inhibitor-based HAART initially became 
available. Typically, these classes are two nucleoside analogue reverse transcriptase 
inhibitors (NARTIs or NNRTI). 
1.9.5.1. Classification of Drugs: 
 Drugs used against the retrovirus in AIDS 
i. Nucleoside and Nucleotide reverse transcriptase inhibitors(NRTI) 
ii. Non- Nucleoside reverse transcriptase inhibitors(NNRTI) 
iii. Protease inhibitors 
iv. Integrase inhibitors 
v. Viral entry inhibitors 
vi. Viral assembly inhibitors 
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Nucleoside and Nucleotide reverse transcriptase inhibitors (NRTI):
              Their intended therapeutic action is to prevent the formation of HIV DNA by 
inhibiting HIV reverse transcriptase.
 Ex: Zidovudine, Stavudine, Didanosine, Zalcitabine, Abacavir, Emtricitabine and 
Azidothymidine (nucleosides) and Tenofovir (nucleotide).
Non- Nucleoside reverse transcriptase inhibitors (NNRTI
          Unlike the nucleoside analo
transcriptase by noncompetitively binding directly to the enzyme downstream from 
the active catalytic site. Ex: Nevirapine, Efavirenz and Delaviridine
.Table 1.1: Currently available nucleoside and nucleotide
inhibitordrugs 
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 Protease inhibitors: 
        This protease cleaves multi domain viral proteins into their active forms; 
blocking this process completely would prevent the virus from being infectious. 
 Ex: saquinavir, Ritonavir, Indinavir, Nefinavir and Lopinavir. 
Integrase inhibitors: 
         Multiple steps in the integration process are catalyzed by HIV-1 integrase. The 
integration of HIV-1 DNA into the host chromosome is achieved by the integrase 
performing a series of cutting and joining reactions. Integrase inhibitors seek to block 
the integrase enzyme from allowing this integration process from happening. 
 Ex: Raltegravir 
Entry inhibitor: 
           An infectious HIV-1 virion consists of a nucleoprotein core surrounded by a 
lipid bi layer membrane derived from the cell that produced the virion. The virus 
membrane and plasma membrane of the host cell represent physical barriers between 
the core and its destination. To breach these barriers, enveloped viruses have evolved 
genes encoding proteins that catalyze the fusion of viral and cellular membranes and 
thereby place the core in the host cell cytoplasm. 
 Ex: Enfuvirtide. 
Viral assembly inhibitors: 
            Assembly and release of HIV-1 are governed by the viral gag and vpu 
proteins. Following its synthesis in the cytosol, gag is rapidly and specifically 
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transported to the site of virus assembly. The goal of these inhibitors is to 
assembly or release by binding to one of components
Figure 1.7: Mechanism of anti retroviral drugs
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 Tenofovir Disoproxil Fumararte is an FDA Approved Prodrug for clinical use 
for the treatment of HIV infection, AIDS and AIDS related conditions either 
alone or in combination with other anti retroviral drugs. 
 Tenofovir is a prodrug form of Tenofovir, which is active in-vitro against 
HIV-1 and HIV-2. Tenofovir disoproxil fumarate is absorbed rapidly 
following oral administration producing peak plasma concentration 
0.30±0.09gm/ml with 25% oral bioavailability. 
 It is usually administered in a dose of 300mg once daily in order to maintain 
effective concentration, and the main dose related adverse effect is renal 
toxicity, with increase in concentrations. 
 The drug has longer half life of 17 hours. Hence it is suitable for immediate 
release preparations. 
 Immediate release drug delivery systems for oral dosing are effective in 
achieving optimal therapy for the drugs that have longer half life. 
 These preparations were able to release immediately with quicker on set of 
action and without dose dumping problem by incorporating super disintegrants 
like Croscarmellose sodium,Crospovidone. 
 So the present work involves use of immediate release system for Tenofovir 
disoproxil fumarate  by incorporating super disintegrants will ensure the drug   
to release the medicament immediatly  for quicker on set of action which will  
increase the patient compliance. 
2. NEED AND OBJECTIVES 
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Objectives: 
 To formulate and evaluate Tenofovir Disoproxil Fumarate immediate release 
Tablet. 
 To study the effect of different superdisintegrants on drug release behaviour 
of the polymer. 
 The objective of the present study is to developed a pharmaceutically                                                        
equivalent, stable and quality improved formulation of immediate release 
Tenofovir disoproxil Fumarate Tablet which is Nucleotide reverse 
transcriptase inhibitors (NRTIs) and these were matched with that of the 
marketed dosage form 
 Based on the Pre and post formulation parameters the best selected 
formulation was subjected to short term stability studies as per ICH 
guidelines. 
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1. Anindita Behara., et al., (2011) had developed the three simple 
Spectrophotometric methods for estimation of Emtricitabine and Tenofovir 
disoproxil fumarate  from tablet dosage form .They are Least square method, 
First order derivative spectroscopy and Area under curve method. 
2. Benjamin H Chi., et al., (2007) had studied A single dose of Tenofovir 
disoproxil fumarate and Emitricitabine at delivery reduced resistance to non-
nucleoside reverse transcriptase inhibitors at 6 week safer delivery by half; 
therefore this treatment should be considered as an adjuvant to intrapartum 
nevirapin. 
3. Biljana Govedarica., et al., (2011) had developed the Formulation and 
evaluation of immediate release tablets with different types of paracetamol 
powders prepared by direct compression. The advantages of the formulation 
with coated PAR for industrial production are decrease of friability and 
superiority in terms of flow ability, compressibility, quick disintegration and 
dissolution. With regards to results, coating of PAR particles has a positive 
effect on manufacturing of tablets with immediate release. 
4. Gupta, D.M. Barends., et al., (2006) had studied the Review of global 
regulations concerning bio waivers for immediate release solid oral dosage 
forms. The regulations with respect to bio waivers for immediate release (IR) 
solid oral dosage forms in the USA, the EU, and Japan and from the World 
Health Organization (WHO) are summarized and compared. Two case studies 
are presented, one from our own files and one from the open literature, 
4. LITERATURE REVIEW 
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showing the similarities and the differences among the qualification 
requirements of the four systems. The regulatory experience gained up to now 
is reviewed and expected future trends are discussed. 
5. Erno A. van Schaick., et al., (2003) had developed Pharmacokinetic 
Comparison of Fast-Disintegrating and Conventional Tablet Formulations of 
Risperidone in Healthy Volunteers. The bioequivalence assessment was based 
on pharmacokinetic and statistical analysis of data from 37 subjects who 
completed both treatment periods. The fast disintegrating tablet and the 
conventional tablet showed bioequivalence with respect to the active moiety, 
Risperidone, and 9-hydroxy-risperidone.In this study in healthy subjects, a 
single administration of two 0.5mg fast-disintegrating Risperidone tablets was 
bioequivalent to a single administration of two 0.5-mg conventional 
Risperidone tablets 
6. Frampton James E., et al., (2006) had developed Tenofovir disoproxil 
Fumarate/ Emtricitabine double combination tablets. A new formulation 
combining fixed doses of the nucleoside reverse transcriptase inhibitors 
Emitricitabine (200mg) and Tenofovir disoproxil fumarate (300mg) represents 
the first once-daily, one- tablet antiretroviral regimen. Co-formulated 
Tenofovir disoproxil Fumarate/ Emtricitabine demonstrated bioequivalence to 
concomitant administration of the individual agents in a pharmacokinetic trial 
in healthy volunteers (n=48). Co-formulated Tenofovir disoproxil 
Fumarate/Emtricitabine has not been evaluated in clinical  
7. Giordano Madeddu., et al., (2008) had studied   both  prevalence  and  
incidence  of  nephro toxicity  were  low  in  patients  receiving  Tenofovir  in  
a  non-selected  clinical  setting. Renal  injury  in patients  in  patients  
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receiving  Tenofovir  seems  associated  with  the  presence  of  co morbidities  
and  with  advanced  HIV infection. 
8. Goutham. M., et al., (2001) had studied the formulation development, 
optimization and In-Vitro evaluation of immediate release folic acid tablets. 
Tablets were prepared containing 40% average using croscarmellose 
sodium,crospovidone, pre gelatinised starch and sodium starch glycolate, as 
disintegrants.Since the tablets contains 10% overages failed to meet the 
desired specifications. During the course of study it was found that the 
Formula G8 containing pre gelatinised starch as disintegran exhibited 
acceptable disitegraion time, percentage drug content per tablet and In-Vitro 
drug release. So at last it was concluded that immediate release folic acid 
tablets containing 40% overages can be prepared using direct compression 
which met the recquired Specifications. 
9. Horatio B. Fung., et al., (2002) had studied Tenofovir disoproxil fumatate has  
exhibited  anti-HIV  activity  in various  HIV-infected  cell  lines  and  has  
produced  a  synergistic  or  additive  effect  against  HIV  when  combined  
with  other  antiretroviral  agents , Tenofovir disoproxil fumarate  appears  to 
be  a  promising  agent  for  the  treatment  of  HIV infection. 
10. Jessica Tan., et al., (2008) had studied Tenofovir Disoproxil Fumarate  
monotherapy is effective for patients with virologic break through  or  
suboptimal  response  to  ADV,  but  combination  therapy  with  a  nucleoside  
analogue  should  be  considered  in  patients  with  ADV-resistance. 
11. Kumar Pradeep., et al., (2011) had developed a simple, accurate, precise and 
rapid high performance thin layer chromatographic method has been 
developed and validated for estimation of Tenofovir in tablet dosage forms. 
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The method employed TLC aluminium plates pre coated with silica gel 60 F 
254 as the stationary phase. the mobile phase used as a mixture of  
(chloroform: methanol8.5:1.50). the detection of spot was carried out at 270 
nm.the calibration curve was found to be linear between 200 to 1200ng ml-1the 
accuracy of proposed method was determined by recovery studiesand found to 
be 98.39 to 101.19%. the method was applicable to Tenofovir in tablet dosage 
form.   
12. Kusum V Devi., et al., (2006) had studied about the Human Immuno 
deficiency Virus (HIV) is a retrovirus that causes irreversible destruction of 
the immune system, leading to the occurrence of opportunistic infections and 
malignancies. . Efforts have been made to design drug delivery systems for 
anti HIV agents to: a) reduce the dosing frequency, b) increase the 
bioavailability and decrease the degradation/metabolism in the gastrointestinal 
tract, c) improve the CNS penetration and inhibit the CNS efflux, and d) 
deliver them to the target cells selectively with minimal side effects. This 
article is an attempt to compile all major research work towards drug delivery 
for AIDS therapy and channel future attempts in the area of more effective 
controlled delivery of anti HIV agents. 
13. Manikandan M., et al., (2012) had Studied the formulation and evaluation of 
Tenofovir  disoproxil fumarate and Emtricitabine immeadiate release tablets 
using different disintegrants like Croscarmellose sodium , Crospovidone. The 
absorbance of Emtricitabine and Tenofovir Disoproxil fumarate was screened 
in the UV region and the maximum was found to be 282nm and258nm 
respectively and this was   used for HPLC analysis. 
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14. Mardia R.B. et al., (2012) had developed a simple, rapid, precise and 
accurate HPTLC method for the estimation of Tenofovir disoproxil fumarate 
was developed and validated. The chromatograms were developed using a 
mobile phase of ethyl acetate:methanol:formic acid(7:2.5:0.5%v/v)on pre-
coated plate of silica gel GF aluminum TLC plate and quantified by 
densitometric absorbance mode at 266nm. T he R1 value for tenofovir  
disoproxil fumarate was 0.78. the linearity of the method was found to be 
within the concentration range of125-750 ng/spot. The lower limits of 
detection and quantification were found to be7.90ng/spot and 23.93ng/spot. 
15. Mary Kay Washington M.D., et al., (2008) had studied Tenofovir Disoproxil 
Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B Tenofovir 
disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of 
human immunodeficiency virus type 1 reverse transcriptase and hepatitis B 
virus (HBV) polymerase. Among patients with chronic HBV infection, 
Tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a 
similar safety profile as compared with Adefovir dipivoxil at a daily dose of 
10 mg through week 48  
16. Michael D. Swanson., et al., (2011) had studied Synergistic in vitro anti-HIV 
type 1 activity of Tenofovir with carbohydrate-binding agents (CBAs). 
Tenofovir, a well-known and highly prescribed anti-HIV-1 drug for the 
treatment of HIV/AIDS infections, has recently also shown its effectiveness as 
a potential microbicide drug in the prevention of HIV transmission. The 
Tenofovir /CBA combinations predominantly showed synergistic antiviral 
activity using the median effect principle. These findings illustrate that 
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combination of Tenofovir  with CBAs may increase the antiviral potency of 
the individual drugs and reducing the risk on potential side-effects.  
17. Michele Di Mascio., et al., (2003) had developed the antiviral activity of 
Tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected 
individuals. The reduction in plasma HIV-1 RNA with TDF mono therapy was 
comparable with the decline observed in previous studies of protease inhibitor 
mono therapy. TDF is a potent antiretroviral agent and has comparable 
inherent antiviral activity with that of ritonavir, a potent protease inhibitor. 
18.  N Appala raju ., et al., (2012) had studied simultaneous stability indicating 
RP-HPLC method is developed for the estimation of Emtricitabine and 
Tenofovir disoproxil fumarate and Efavirenz in tablet dosage form 
.Chromatography was carried on an inertsil ODS 3V column using gradient 
composition of 0.02M sodium di hydrogen orthophosphate as mobile phase A 
and mixture of Methanol and water in the ratio of 85:15 as mobile phase at a 
flow rate of 1.5ml/min with detection at 265 nm. 
19. Narendra Devanaboyina., et al., (2012) had developed a simple, rapid 
reverse phase High Performance Liquid Chromatographic method was 
developed and validated for the simultaneous estimation Tenofovir and 
Emtricitabine in bulk and pharmaceutical dosage forms. Chromatography was 
carried out by using Chromosil C-18, column having 250×4.6mm internal 
diameter with a mixture of methanol Acetonitrile and TEA in ratio of 
46:50:04(v/v/v) as mobile phase. 
20. Ravi V. K., et al., (2009) had studied optimization of Immediate release tablet 
of Raloxifene hydrochloride by wet granulation method developed different 
filler, binder, disintegrant and lubricant were taken as variable weight 
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variations, thickness, hardness, friability, disintegration time in-vitro release 
and pharmaceuticals assay well studied as response variables. Optimization 
has proven as an effective tool in product development. 
21. Syed Azeem., et al., (2011) had developed the rupatadine fumarate for rapid 
action. Direct compression method was adopted to prepare tablets by using 
mannitol, mcc as filler, crospovidone,alginic acid, sodium cmc as 
superdisintigrantsin different concentrations (2-5%). Total twelve 
formulations and one control were prepared. And evaluated for hardness, 
friability, wt variation, content uniformity, wetting time, water absorption 
ratio, disintegration time and In-Vitro drug release. 
22. Shirkehedkar Atul A et al., (2009) had developed two new, simple and cost 
effective UV- Spectrophotometric and first order derivative methods were 
developed for estimation of Tenofovir disoproxil fumarate in bulk and tablets. 
Tenofovir disoproxil fumarate was estimated at 260nm 1n 0.1 NHCl. In first 
order derivative., it showed amplitude at 273nm. In both methods it shows 
linearity was found to be in the range of 5-40 µg/ml., for UV- 
Spectrophotometric method (Y=0.02586 X+0.0083., r2=0.9999) and for first 
order derivative spectrophotometric method )Y=0.00132 X+0.00035., 
r2=0.9995) respectively.   
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  5.1. DRUG PROFILE:    
 (http://www.en.wikipedia.org/wiki/Tenofovir ) 
 Name of the drug:  
                 Tenofovir Disoproxil Fumarate 
 Chemical Name: 
                    9-[(R)]-2-[bis [(cisoproxycarbonyl) oxy] methoxy] propyl] adenine 
fumarate (1:1) 
 Molecular Formula: C19 H30 N5 O5 P.C4H4O4 
 Molecular weight:     635.52 
 CAS number: [147127-20-6] 
 Structure:                                          
                                             
 Category: 
          Antiviral for systemic use, nucleoside and nucleotide reverse transcriptase 
inhibitors. 
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 Dose: 
             Tenofovir  is  efficiently  removed  by  haemodialysis  with  an  extraction  
coefficient  of  approximately  54%.  Following  a  single  300  mg  dose  of  
Tenofovir disoproxil fumarate a  four-hour  haemodialysis  is  session  removed  
approximately 10% of the administered Tenofovir  dose 
              The dose of VIREAD is 300 mg once daily taken orally, without regard to 
food. In the treatment of chronic hepatitis B, the optimal duration of treatment is 
unknown 
 Over dosage 
                  Limited clinical experience at doses higher than the therapeutic dose of 
Tenofovir disoproxil fumarate 300 mg is available. In Study 901, 600 mg Tenofovir 
disoproxil fumarate was administered to 8 patients orally for 28 days. No severe 
adverse reactions were reported. The effects of higher doses are not known. If 
overdose occurs the patient must be monitored for evidence of toxicity, and standard 
supportive treatment applied as necessary. 
                Tenofovir is efficiently removed by haemodialysis with an extraction 
coefficient of approximately 54%. Following a single 300 mg dose of Tenofovir 
disoproxil fumarate, a four-hour haemodialysis session removed approximately 10% 
of the administered Tenofovir dose. 
 Dose form: Tablets 
 Description: White to off- white crystalline powder. 
 Solubility 
       Freely soluble in dimethyl formamide and soluble in methanol; It has 
solubility of 13.4 mg/ml in distilled water at 25˚C. 
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 Storage:  
                 Store protected from light in a refrigerator (2˚C to 8˚C), Store between 
15˚C-30 °C (59-86 °F). 
 Melting point: 114˚C to 118˚C 
 Pka: 7.91 
 Hygrosopicity: Non –hygroscopic 
PHRMACOLOGY: 
 Pharmacodynamics: 
          Tenofovir disoproxil fumarate is an antiviral drug. Tenofovir disoproxil 
fumarate is an acyclic nucleoside phosphonate diester analogue of adenosine 
monophosphate. Tenofovir disoproxil fumarate requires initial di ester hydrolysis for 
conversion to Tenofovir and subsequent phosphorylations by cellular enzymes to 
form Tenofovir diphosphate, an obligate chain terminator. Tenofovir di phosphate 
inhibits the activity of HIV-1 reverse transcriptase and HBV reverse transcriptase by 
competing with the natural substrate deoxyadenosine 5’-triphosphate and, after 
incorporation into DNA, by DNA chain termination. Tenofovir di phosphate is a weak 
inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA 
polymerase gamma. 
Pharmacokinetics: The pharmacokinetics of Tenofovir disoproxil fumarate has been 
evaluated healthy volunteers and HIV-1 infected individuals. Tenofovir 
pharmacokinetics is similar between these populations. 
Absorption: 
tmax     : 1.0±0.4 hrs 
Cmax     : 0.30± 0.09 g/ml 
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AUC        : 2.29± 0.69 g.hr/ml  
Half life : Approximately 17hrs 
Tenofovir disoproxil fumarate is a water soluble diester prodrug of the active 
ingredient Tenofovir. The oral bioavailability of Tenofovir disoproxil fumarate in 
fasted subjects is approximately 25%. The pharmacokinetics of Tenofovir are dose 
proportional over a Tenofovir disoproxil fumarate dose range of 75 to 600mg and are 
not affected by repeated dosing. 
Distribution:  
  In-vitro binding of Tenofovir to human plasma or serum proteins is less than 
0.7 and 7.2% respectively, over the Tenofovir concentration range 0.001 to 25µg/ml. 
The volume of distribution at steady state is 1.3± 0.6 L/kg and 1.2 ± 0.4 L/kg 
following intravenous administration of Tenofovir 1.0mg/kg. 
Metabolism: 
Neither Tenofovir disoproxil nor Tenofovir are substracts of cyp 450 enzymes 
these variations in response and side effects are caused by many variables, but genetic 
variation and metabolism-based drug, herbal, and food interactions are among the 
most common. 
Elimination: 
          Tenofovir is eliminated by a combination of glomerular filteration and active 
tubular secretion. There may be competition for elimination with other compounds 
that are also renally eliminated. 
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 Mechanism of Action: 
               Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester 
analogue of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial 
diester hydrolysis for conversion to Tenofovir and subsequent phosphorylations by 
cellular enzymes to from Tenofovir diphosphate, an obligate chain terminator. 
Tenofovir diphosphate inhibits the activity of HIV-1 reverse transcriptase and HBV 
polymerase by competing with the natural substrate deoxyadenosine 5’-triphosphate 
is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA 
polymerase γ. 
 
 
    Figure5.1: Mechanism of action of Tenofovir Disoproxil fumarate 
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 Drug Interactions: 
         This section describes clinically drug interactions with VIREAD. Drug 
interactions studies are described elsewhere in the labelling 
 
Didanosine: 
  Coadministration of Tenofovir disoproxil fumarate and didanosine should be 
undertaken with caution and patients receiving this combination should be monitored 
closely for didanosine- associated adverse reactions. Didanosine should be 
discontinued in patients who develop didanosine- associated adverse reaction 
Atazanavir: 
  Atazanavir has been shown to increase Tenofovir concentrations. The 
mechanism of this interaction is unknown. Patients receiving atazanavir and  
VIREAD should be monitored for Tenofovir-associated adverse reactions. VIREAD 
should be discontinued in patients who develop Tenofovir-associated adverse 
reactions. Tenofovir decreases the AUC and Cmin of atazanavir. When co 
administered with VIREAD, it is recommended that atazanavir 300 mg is given with 
ritonavir 100 mg. Atazanavir without ritonavir should not be co administered with 
VIREAD. 
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INDICATIONS: 
 HIV infection: 
            VIREAD tablets are indicated in combination with other antiretroviral agents 
for the treatment of HIV-1 infection in adults and paediatric patients 12 years of age 
and older. 
               The following points should be considered when initiating therapy with 
VIREAD for the treatment of HIV-1 infection. 
Chronic Hepatitis B: 
          VIREAD is indicated for the treatment of chronic hepatitis B in adults. The 
following points should be considered when initiating therapy with tenofovir 
disoproxil fumarate for the treatment of HBV infection. This indication is based 
primarily on data from treatment of subjects who were nucleoside-treatment-naïve 
and a smaller number of subjects who had previously received lamivudine or adefovir 
dipivoxil. Subjects were adults with HBeAg positive and HBeAg-negative chronic 
hepatitis B with compensated liver disease. Tenofovir was evaluated in a limited 
number of subjects with chronic hepatitis B and de compensated liver disease. 
 Activity against HIV: 
           Antiviral Activity: 
                     The  antiviral  activity  of  Tenofovir  against  laboratory  and  clinical  
isolates  of  HIV-1 was assessed  in  lymphoblastoid  cell lines, primary 
monocyte/macrophage  cells and peripheral blood lymphocytes. 
 
Tenofovir Disoproxil fumarate immediate release tablets Drug & Excipients Profile 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 53 
 
 Resistance: 
             HIV-1 isolates with reduced susceptibility to Tenofovir have been selected in 
cell culture. The viruses expressed a K65R substitution in reverse transcriptase and 
showed a 2-4 fold reduction in susceptibility to Tenofovir. 
 Side  Effects : 
  Lactic Acidosis / severe hepatomegaly with statuses, severe acute                                                                     
exacerbation   of hepatitis new onset or worsening renal impairment decreases in bone 
mineral density, immune reconstitution syndrome. 
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5.2. EXCIPIENTS PROFILE: 
5.2.1. CROSCARMELLOSE SODIUM:               
  (Raymond C. Rowe., et al., 2006) 
1. Nonproprietary names: BP   
             Croscarmellose sodium, Ph Eur: Croscarmellose sodium, USP-NF: 
Croscarmellose sodium. 
2. Synonyms:  
             Ac-Di-Sol; cross linked Carboxymethylcellulose sodium, Explocel, modified 
cellulose gum,  Nymcel ZSX,  Pharmacel XL,  Primellose, Solutab, Vivasol. 
3. Chemical name: 
Cellulose, Carboxymethyl ether, sodium salt. 
4. CAS number: [74811-65-7]  
5. Functional category:  
Tablet and capsule disintegrants. 
6. Structural formula: 
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7. Applications in pharmaceutical formulation or technology: 
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules (10-25%), tablets (0.5%-5%). In tablet formulations, 
Croscarmellose sodium may be used in both direct-compression and wet-granulation 
processes. When used in wet granulations, as intra and extra granular portions 
wicking and swelling ability of the disintegrant is best utilized. Croscarmellose 
sodium at concentrations up to 5% w/w may be used as a tablet disintegrant, although 
normally 2% w/w is used in tablets prepared by direct compression and 3% w/w in 
tablets prepared by a wet-granulation process.  
8. Description:  
Croscarmellose sodium occurs as an odourless, white or greyish white powder. 
9. Solubility:  
            Insoluble in water, although Croscarmellose sodium rapidly swells to 4–8 
times its original volume on contact with water. Practically insoluble in acetone, 
ethanol and toluene. 
10. Safety:  
  Croscarmellose sodium is mainly used as a disintegrant in oral 
pharmaceutical formulations and is generally regarded as an essentially nontoxic and 
non irritant material. However, oral consumption of large amounts of Croscarmellose 
sodium may have a laxative effect, although the quantities used in solid dosage 
formulations are unlikely to cause such problems. 
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5.2.2. CALCIUM CARBOXY METHYL CELLULOSE: 
(Raymond C. Rowe., et al., 2006) 
 1. Nonproprietary names: 
           BP: Carmellose calcium, PhEur: Carmellose calcium, USP-NF: Carboxy 
methyl cellulose calcium. 
2. Synonyms:  
         Calcium carboxymethylcellulose, Calcium cellulose glycolate, Carmellosum 
Calcium,Carboxy methyl cellulose calcium.  
3. Chemical name: 
Cellulose, carboxymethyl ether, calcium salt. 
4. CAS number: [74811-65-7]  
5. Functional category:  
Emulsifying agent, Coating agent, Stabilizing agent, Tablet and capsule 
disintegrants, Viscosity increasing agent, Water absorbing agent. 
6. Structural formula: 
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 7. Applications in pharmaceutical formulation or technology: 
            Calcium carboxy methyl cellulose  is used in oral pharmaceutical formulations 
as a disintegrant for  tablets (0.5%-5%) and tablet binder(5-15%). In tablet 
formulations, Calcium carboxy methyl cellulose may be used in both direct-
compression and wet-granulation processes. When used in wet granulations, as intra 
and extra granular portions wicking and swelling ability of the disintegrant is best 
utilized. 
 . 8. Description:  
Calcium carboxy methyl cellulose occurs as an white or Yellowish white 
powder, hygroscopic, odourless powder. 
9. Solubility:  
           Insoluble in acetone, chloroform, ethanol (95%), toluene and ether, Insoluble 
in water, But swells to form a suspension. 
 10. Stability and storage conditions: 
          Carboxy methyl cellulose calcium is stable, through hygroscopic material, It 
should be stored in a well closed container in a cool, dry place. 
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5.2. 3. MAGNESIUM STEARATE: 
(Raymond C. Rowe., et al., 2006) 
1. Non-proprietary names:  
  BP: Magnesium stearate, JP: Magnesium Stearate, PhEur: Magnesium 
Stearate, USP-NF: Magnesium Stearate.  
2. Synonyms:  
  Dibasic magnesium Stearate, magnesium distearate, magnesium 
octadecanoate, octadecanoic acid, magnesium salt, stearic acid, magnesium salt,  
Synpro 90. 
3. Chemical name:  
Octadecanoic acid magnesium salt. 
4. Structural formula: 
 [CH3 (CH2)16COO]2 mg. 
5.Functionalcategory: 
  Tablet and capsule lubricant. 
6. Applications in pharmaceutical formulation or technology: 
 Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.  
 7. Description:  
 Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odour of Stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
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8. Melting range: 
 117˚C–150˚C(commercial samples), 126˚C–130˚C (high purity magnesium 
stearate). 
9. Solubility:  
 Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
10. Safety: 
 Magnesium Stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may produce a laxative effect or mucosal irritation. 
No toxicity information is available relating to normal routes of occupational 
exposure. 
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5.2.4. LACTOSE: 
(Raymond C. Rowe., et al., 2006)  
1 .Non-proprietary names:   
  BP: Anhydrous lactose, JP: Anhydrous lactose, Ph Eur: Lactose anhydrous, 
USP-NF: Anhydrous lactose. 
2. Synonyms: 
 Anhydrous 60M; Anhydrous direct tableting , Anhydrous Impalpable, 
Lactopress anhydrous,  Lactopress Anhydrous 250, Lactosum anhydricum. 
3. Chemical name:  
          O-β-D-Galactopyranosyl-(1, 4)-β-D –glucopyranose.  
4. CAS number: [64044-51-5] 
5. Molecular formula: C12 H22O11. 
6. Molecular weight: 342.30. 
7.  Structural formula: 
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             USP32–NF27 describe anhydrous lactose as O-β- D-galactopyranosyl-(1,4)-
β-D-glucopyranose or a mixture of O-β-D-galactopyranosyl-(1,4)- α -D-
glucopyranose and O-β-D-galactopyranosyl-( 1,4)-β-D-glucopyranose. The JP XV 
describes anhydrous lactose as β-lactose or a mixture of β-lactose and α-lactose.  
8. Functional category:  
             Directly compressible tablet excipient, dry powder inhaler carrier, 
lyophilisation  aid, tablet and capsule diluent, tablet and capsule filler. 
9. Applications in pharmaceutical formulation: 
  Anhydrous lactose is widely used in direct compression tableting 
applications, and as a tablet and capsule filler and binder. Anhydrous lactose can be 
used with moisture-sensitive drugs due to its low moisture content. It may also be 
used in intravenous injections.     
9. Description: 
 Lactose occurs as white to off-white crystalline particles or powder. It is 
odourless and slightly sweet-tasting.                         
10. Solubility:  
Soluble in water, sparingly soluble in ethanol (95%) and ether, 40 g/100mL at 
250˚ C. 
11. Safety: 
 Lactose is widely used in pharmaceutical formulations as a diluent in oral 
capsule and tablet formulations, and has a history of being used in dry powder inhaler 
formulations. 
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5.2.5. MICROCRYSTALLINE CELLULOSE: 
  (Raymond C Rowe., et al., 2006) 
1. Non-proprietary names: 
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline  
USP-NF: Microcrystalline Cellulose 
2. Synonyms: 
  Avicel pH, Celex, cellulose gel, Celphere, Ceolus,Crystalline cellulose, 
E460, Emcocel, Fibrocel, Pharmacel, Tabulose,Vivapur. 
3. Chemical Name: Cellulose.  
4 .CAS number: [9004-34-6] 
5. Empirical Formula & Molecular Weight: (C6 H10O5)n  ;   36,000 
6. Structural Formula: 
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7. Functional Category: 
Adsorbent, suspending agent, tablet and Capsule diluents, tablet disintegrant. 
 
8. Applications in Pharmaceutical Formulation or Technology:      
                           Microcrystalline cellulose is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule formulations .Microcrystalline 
cellulose is also used in cosmetics and food products. 
                             
                               Table 5.1: Uses of Microcrystalline cellulose 
Use Concentration (%) 
Adsorbent 20-90 
Anti-adherent 5-20 
Capsule binder/diluents 20-90 
Tablet disintegrant 5-15 
Tablet binder/diluents 20-90 
 
9. DISCRIPTION:  
            Microcrystalline cellulose is purified, partially depolymerised cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. 
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          Table 5.2:  Properties  of  Commercial  grades  of  Microcrystalline cellulose 
Grade Nominal mean particle size 
Avicel pH-101 50 
Avicel pH-102 100 
Avicel pH-103 50 
Avicel pH-105 20 
 
10. Stability and Storage Conditions: 
                    Microcrystalline cellulose is a stable, though hygroscopic material. The 
bulk material should be stored in a well-closed container in a cool, dry, place. 
11. Incompatibilities: 
               In compatible with strong oxidizing agents.  
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5.2.6. STARCH, PREGELATINISED:                    
  (Raymond C. Rowe., et al, 2006) 
 
1. Nonproprietary Name: 
BP: Pre gelatinised starch. 
PhEur: Amylum pregelificatum. 
USPNF: Pre gelatinized starch. 
 
2. Synonyms: 
          Compressible starch; Instastarch; Lycatab C; Lycatab PGS; Merigel; National 
78-1551; Pharma-Gel; Prejel; Sepistab ST 200; Spress B820; Starch 1500 G; Tablitz; 
Unipure LD; Unipure WG220. 
 
3. Chemical Name: Pre gelatinised starch. 
4. Empirical Formula and Molecular Weight: 
                           (C6H10O5)n where n = 300–1000. Pre gelatinised starch is a starch 
that has been chemically and/or mechanically processed to rupture all or part of the 
starch granules and so render the starch flowable and directly compressible. Partially 
pre gelatinised grades are also commercially available. Typically, pre gelatinised 
starch contains 5% of free amylose, 15% of free amylopectin, and 80% unmodified 
starch. The USPNF 23 does not specify the botanical origin of the original starch, but 
the PhEur 2005 specifies that pre gelatinised starch is obtained from maize (corn), 
potato, or rice starch. 
 5. Functional Category: 
Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder.  
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6. Description: 
Pre gelatinised starch occurs as a moderately coarse to fine, white to off-white 
coloured powder. It is odourless and has a slight characteristic taste. Examination of 
fully pre gelatinised starch as a slurry in cold water, under a polarizing microscope, 
reveals no significant un gelatinised granules, i.e., no ‘maltese crosses’ characteristic 
of the starch birefringence pattern. Examination of samples suspended in glycerin 
shows characteristic forms depending upon the method of drying used during 
manufacture: either irregular chunks from drum drying or thin plates. Partially pre 
gelatinised starch (e.g., Starch 1500G and Sepistab ST200) show retention of 
birefringence patterns typical of unmodified starch granules. 
7. Solubility:  
              Practically insoluble in organic solvents. Slightly soluble to soluble in cold 
water, depending upon the degree of pre gelatinisation. Pastes can be prepared by 
sifting the pre gelatinised starch into stirred, cold water. Cold-water soluble matter for 
partially pre gelatinised starch is 10–20%. 
 
8. Applications in Pharmaceutical Formulation: 
 
                    Pre gelatinised starch is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent, and disintegrant. In comparison to starch, grades of 
pre gelatinised starch may be produced with enhanced flow and compression 
characteristics such that the pre gelatinised material may be used as a tablet binder in 
dry-compression or direct compression processes. In such processes, pre gelatinised 
starch is self lubricating. However, when it is used with other excipients it may be 
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necessary to add a lubricant to a formulation. Although magnesium stearate 0.25% 
w/w is commonly used for this purpose, concentrations greater than this may have 
adverse effects on tablet strength and dissolution. Therefore, stearic acid is generally 
the preferred lubricant with pre gelatinised starch. Pre gelatinised starch may also be 
used in wet granulation processes.  
9. Storage:  
             Pre gelatinised starch should be stored in a well-closed container in a cool, 
dry place. 
10. Safety: 
             Pre gelatinised starch and starch are widely used in oral solid dosage 
formulations. Pre gelatinised starch is generally regarded as a nontoxic and non 
irritant excipient. However, oral consumption of large amounts of pre gelatinised 
starch may be harmful. 
                                   
 
                             Table 5.3: Uses of Pre gelatinised starch 
Use Concentration (%) 
Diluent(hard gelatin capsules) 5-75 
Tablet binder (direct compression) 5-20 
Tablet binder (wet granulation) 5-10 
Tablet disintegrant 5-10 
 
12. Regulatory Status: 
             Included in the FDA Inactive Ingredients Guide (oral capsules, suspensions, 
and tablets; vaginal preparations). Included in nonparenteral medicines licensed in the 
UK.  
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5.2.7. CROSPOVIDONE: 
(Raymond C Rowe., et al., 2006) 
1.Non-proprietary Name:  
BP:   Crospovidone. 
Eur:  Cros povidonum 
USP NF:  Crospovidone 
 
2.Synonyms: 
           Crospovidonum; Polyplasdone XL; Polyvinylpolypyrrolidone,E1202; Kollidon 
CL;Kollidon CL-M. 
3. Chemical Name:  
             1-Ethenyl-2-pyrrolidinone homopolymer. 
4. CAS Register Number: 
       [9003-39-8]. 
5. Description:  
              Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odourless or nearly odourless, hygroscopic powder. 
 
6. Empirical Formula and Molecular Weight: 
              (C6H9NO) n, 2.500 - 2.5000.000 g·mol−1  
 
7. Molecular structure: 
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8. Functional Category
        Tablet disintegrant
9. Solubility: 
         Practically insoluble in water and most common organic solvents.
10. Stability and Storage Conditions:
        Since Crospovido
in a cool, dry place.
11. Incompatibilities:
       
         Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a hi
molecular adducts with some materials.
12. Applications:  
         
           Crospovidone is a water
used at 2-5 % concentration in tablets prepared by direct compre
dry-granulation methods. It can also be used as a solubility enhancer.
13. Related Substances
           Crospovidone, povidone.
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5.2.8. POVIDONE:                                                   
(Raymond C. Rowe., et al., 2006) 
  1. Non-proprietary Names 
BP: Povidone                                  
Eur: Povidonum                        
 USP: Povidone 
2. Synonyms 
        E1201;Kollidon;Plasdonepoly[1-(2-oxo-1-pyrrolidinyl)ethylene],polyvidone 
;polyvinylpyrrolidone, PVP; 1-vinyl-2-pyrrolidinone polymer. 
3. Chemical Name and CAS Registry Number 
         1-Ethenyl-2-pyrrolidinone homopolymer, [9003-39-8]. 
4. Empirical Formula and Molecular Weight 
(C6 H9NO)n 2500–3 000 000 
K-value                         Approximate molecular weight 
12                                             2500 
15                                             8 000 
17                                             10 000 
25                                             30 000 
30                                             50 000 
60                                             400 000 
90                                             1 000 000 
5. Functional Category 
Disintegrant; dissolution aid; suspending agent; tablet binder. 
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6. Description 
Povidone occurs as a fine, white to creamy-white coloured, odourless, 
hygroscopic powder. 
7. Structural Formula 
      
8. Typical Properties 
Acidity/alkalinity: pH = 3.0–7.0 (5% w/v aqueous solution). 
Melting point: softens at 150°C. 
Moisture content: 
          Povidone is very hygroscopic, significant amounts of moisture being absorbed 
at low relative humidities.  
Solubility:  
          Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, the 
concentration of a solution is limited only by the viscosity of the resulting solution. 
Viscosity (dynamic): 
         The viscosity of aqueous Povidone solutions depends on both the concentration 
and the molecular weight of the polymer employed.  
9. Applications in Pharmaceutical Formulation or Technology 
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  Although Povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tablets, Povidone solutions are used as 
binders in wet-granulation processes. Povidone is also added to powder blends in the 
dry form and granulated in situ by the addition of water, alcohol, or hydro alcoholic 
solutions.  
                                  Table 5.4: Uses of Povidone. 
USE CONCENTRATION (%) 
Carrier for drugs 10-25 
Dispersing agent Up to 5 
Eye drops 2-10 
Suspending agent Up to 5 
Tablet binder, diluents, dispersing agent 0.5-5 
 
10.  Stability and Storage Conditions 
  Povidone darkens to some extent on heating at 150°C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–130°C; 
steam sterilization of an aqueous solution does not alter its properties.  
11.  Incompatibilities 
   Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals.  
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 6.1. LIST OF EQUIPMENTS: 
 
                    Table 6.1: List of Equipments used in formulation 
 
   S.NO NAME OF INSTRUMENTS MODEL AND MANUFACTURER 
1 Digital Balance Mettler Toledo PR203, China 
2 Rapid Mix Granulator RMG5 Anchor Mark Pvt Ltd.,Mumbai 
3 Fluid bed dryer Umang Pharma tech Pvt Ltd., Mumbai 
4 Moisture Analyzer Advance Research Pvt Ltd., Mumbai 
5 Tap Density Tester Electrolab, Mumbai 
6 Differential Scanning Calorimeter Shimadzu DSC 60, Japan 
            7 Tablet compression machine Rimek1rotary , Ahmedabad 
8 Vernier Calliper Mitutoyo, China 
9 Hardness Tester SQC&Inspection instruments, Mumbai 
           10 Disintegration Apparatus USP Tab machines, Mumbai 
          11 Stability chamber Cintex Ind. Corporation, Mumbai 
          12 Mechanical Stirrer Neocota, Mumbai 
          13 Auto coater Neocota, Mumbai 
          14 DissolutionApparatusUSP XXII ElectroLab, Ahmedabad 
          14 HPLC with Autosampler Waters, USA 
          15 pH meter Metro HM, Switzerland 
 
6. MATERIALS AND EQUIPMENTS 
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6.2. LIST OF RAW MATERIALS: 
                    Table 6.2:  list of Raw materials used in formulation 
S .No. Drug/Excipients Name of supplier 
1 Tenofovir Disoproxil Fumarate Natco Pharma Ltd., Hyderabad 
2 Micro crystalline cellulose Brahmar cellulose Pvt Ltd.,cuddalore 
3 Lactose monohydrate Vijilak pharma, Mumbai 
4 Calcium carboxy methyl cellulose Natco Pharma Ltd., Hyderabad 
5 Crospovidone SD Fine –Chem Pvt, Mumbai 
6 Hydroxy propyl cellulose Brahmar cellulose Pvt Ltd., cuddalore 
7 PovidoneK-30 SD Fine –Chem Pvt, Mumbai 
4 Croscarmellose sodium Natco Pharma Ltd., Hyderabad 
5 Pregeratinized starch Signet chemical corporation Pvt Ltd. 
6 Magnesium stearate SD Fine –Chem Pvt, Mumbai 
7 Opadry II Blue(Y-30-1070) Colorcon Asia Pvt Ltd., Mumbai 
 
  
 
 
 
EXPERIMENTAL 
WORK 
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7.1. PREFORMULATION STUDIES:                                
  (Lachman L., et al, 1991). 
 
             Pre formulation testing is an investigation of physical and chemical properties 
of a drug substance alone and when combined with excipients. It is the first step in the 
rational development of dosage forms.  
Objective: 
 The overall objective of Preformulation testing is to generate information 
useful to the formulation in developing stable and bio available dosage forms. 
Scope: 
 The use of Preformulation parameters maximizes the chances in formulating 
an acceptable, safe, efficacious and stable product. 
 
7.1.1. Identification of Drug: 
7.1.1.1. Identification of drug by HPLC method:                                  (IP, 2010) 
 
             In the Assay, the principal peak in the chromatogram obtained with the test 
solution corresponds to the peak in the chromatogram obtained with the reference 
solution. 
 
 
 
7. EXPERIMENTAL WORK 
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7.1.1.2. Identification of drug by melting point: 
            The temperature at which the first particle of the substance completely melts is 
regarded as melting point of the substance. The temperature at which the first particle 
starts to melt and last particle completely melts is regarded as the range of melting 
point.  Melting point of the drug was determined by capillary tube method. 
7.1.2. Physicochemical parameters: 
 
7.1.2.1. Organoleptic properties:      
 (Lachman L., et al.,1991; Bankar G.S  and Rhodes  C.T., 1996) 
  The colour, odour and taste of the drug were recorded using descriptive 
terminology. 
7.1.2.2. Solubility study:                                                                               
                                                                                                                        (IP, 2007)                                          
              It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian pharmacopoeia, 2007. 
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 SOLUBULITY SPECIFICATION: 
                                   Table 7.1: Solubility specifications 
Descriptive terms. 
Approximate volume of solvent in milliliters 
per gram of solvent. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 1 to 30 
Sparingly soluble From 30to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 100 to 10,000 
Practically insoluble More than 10,000 
 
7.1.2.3. Loss on drying:                                                                                  
                                                                                                                         (IP, 2010) 
                Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The accurately weighed 1gm of sample was transferred in glass-stoppered, 
shallow weighing bottle and accurately weighed the bottle. The bottle was transferred 
in oven and substance was dried at 105°C for 3 hours. The bottle was removed from 
oven and reweighed; loss on drying was calculated by following equation, 
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7.1.3. Analytical methods: 
7.1.3.1. Preparation of standard curve:          
                                                                                          (Appala raju  N., et al., 2009) 
Linearity: 
             The linearity of the response for Tenofovir disoproxil Fumarate was 
determined by preparing suitable dilutions were made 12-60µg/ml from standard 
stock solution. All the solutions were injected and the chromatograms were recorded 
at 260 nm. The above concentration range was found to be linear and obeys Beer’s 
law. The procedure was repeated for three times. The peak areas were plotted against 
concentration and the calibration curve was constructed. 
7.1.3.2. Determination of percentage purity of drug:                            
                                                                                                                     (IP, 2010) 
            Although the specifications for assay results differ from product to product, 
generally the expected range for individual active ingredient is to be within 97%–
102% of the labelled amount.  
 Instrument: 
             HPLC equipped with UV detector and data handling system. 
 Apparatus: 
            Analytical balance, volumetric flasks, Pipettes, 0.45µ membrane filters. 
 Chemicals and reagents: 
• Potassium dihydrogen phosphate-GR grade 
• Ortho-phosphoric acid-HPLC grade 
• Purified water-Milli-Q grade 
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• Acetonitrile-HPLC grade 
• Tenofovir disoproxil fumarate working standard 
 Chromatographic conditions: 
• Column: A Stainless steel column packed with Octadecyl silane bonded to 
porous silica (5µm) 
• Flowrate:1.0ml/min 
• Wavelength:-260 nm 
• Column temperature:30˚c 
• Injection volume:10µl 
• Run time: 12 min. 
 Preparations: 
1. Buffer preparation: Accurately weighed and transferred about 4.4 gm of 
Potassium dihydrogen phosphate into 1000 ml of purified water. Adjusted 
the pH of solution to 3.0 with dilute Ortho-phosphoric acid. 
2. Mobile phase –A preparation:  Prepared a filtered and degassed mixture 
of buffer and Acetonitrile in ratio of 70 :30 v/v respectively. 
3. Mobile phase –B preparation: Prepared a filtered and degassed 
Acetonitrile –HPLC grade. 
4. Diluents preparation: Mix buffer and Acetonitrile in ratio of 60:40 v/v 
respectively. 
5. Tenofovir disoproxil fumarate Reference preparation: 
                        A 0.1% W/V solution of Tenofovir disoproxil fumarate  RS in the 
mobile phase. Diluted 5.0 ml of the solution to 50.0 ml with the mobile phase. 
6. Sample preparation: 
                        Dissolved 50 mg of the substance under examination in 50.0 ml of the 
mobile phase diluted 5.0 ml of the solution to 50.0 ml of the mobile phase.  
Tenofovir Disoproxil fumarate immediate release tablets Experimental Work 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 80 
 
7. Procedure: 
                    Seperately inject equal volumes (about 20µl) of the water as blank, 
standard preparation and sample preparation into column and recorded the 
chromatograms and measure the peak area response for analyte peak. Calculate the 
percentage content of  Tenofovir disoproxil fumarate taken by formula. 
 Percentage content of Tenofovir disoproxil fumarate 
= TA / SA *   SW / 250 *   2/20   *   250/TW   * 100/1 * P/100 *    100                   
Where, 
TA = Peak area response due to Tenofovir disoproxil fumarate from sample 
preparation. 
SA= Peak area response due to Tenofovir disoproxil fumarate from standard 
preparation. 
SW=Weight of Tenofovir disoproxil fumarate  working standard taken in mg. 
TW=Weight of sample taken in mg. 
P=Purity of Tenofovir Disoproxil fumarate working standard taken on its basis. 
7.1.4. Determination of Drug-Excipient compatibility:  
 (Vasanth Kumar  S., et al., 2008) 
           A Compatibility study focuses on a binary mixture of drug substance and some 
selected excipients in a fixed ratio with or without added moisture. The mixture is 
stored at elevated temperature 40˚ C±2˚C/75%±5%RH, 25˚C± 2˚C/60%±5%RH in 
capped vials. The result of the interaction between the active drug and excipients is 
determined by HPLC. 
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Procedure: 
 Drug and Excipients mixture shall be prepared based on the information from 
Physician Desk Reference (PDR). 
 The Drugs and Excipients individually and in combination shall be subjected 
for accelerated study conditions along with control samples and study at fixed 
intervals. 
 The recommended drug- Excipients ratios for solid dosage forms are tabulated 
Table 7.2:  Drug - Excipient ratios for Compatibility study of solid dosage forms 
 
Name of Excipient 
Quantity of Drug in mg 
> 5 mg 
5 ≤ 
10mg 
10 ≤ 
50mg 
50 ≤ 
200mg 
200 ≤ 
500mg 
≥500 
mg 
Fillers & Diluents 1:40 1:20 1:10 1:5 1:2 1:1 
Disintegrants / 
Polymers 
1:10 1:5 1:1 1:1 1:0.5 1:0.25 
Binders 1:10 1:5 1:1 1:0.5 1:0.25 1:0.1 
Lubricants 1:0.5 1:0.5 1:0.25 1:0.1 1:0.05 1:0.05 
Coatingagents 1:5 1:5 1:1 1:0.5 1:0.25 1:0.1 
Colours / Sweetners 1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 
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8. Detection of impurities:                                                              
(IP, 2010) 
1. Preparation of sample solution: Dissolved 100mg of the substance 
under examination in 50ml of methanol. 
2. Preparation of Reference solution (a): A 0.2%W/V solution of 
Tenofovir disoproxil fumarate RS in methanol. 
3. Reference solution (b): Diluted 1.0 ml of reference solution (a) to 
100.0ml with methanol. 
4. Reference solution(c): Dissolved 10 mg the fumaric acid in 50 ml of 
methanol. 
 Chromatographic condition : 
 Column: A Stainless steel column 25cm×4.6mm, packed with 
Octadecyl silane bonded to porous silica(5µm) 
 Column Temperature: 30˚C 
 Mobile phase A: 0.1M ammonium acetate solution with the pH 
adjusted to3.8 with glacial acetic acid 
 Mobile phase B: A mixture of 70 volumes of methanol and 30 
volumes of Acetonitrile 
 Flow rate: 1.5 ml per minute 
 Wave length: 260nm 
 Injection volume:10µl 
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Impurity specifications: 
               Table7.3: Impurity standards for Tenofovir disoproxil fumarate. 
S.NO IMPURITY STANDARDS 
1 Tenofovir NMT0.15 
2 Adenine NMT0.15 
3 Monoester NMT1.0 
4 Ethyl NMT0.15 
5 Carbonyl NMT0.15 
6 Isopropyl NMT0.30 
7 Total NMT2.0 
 
7.1.4.1. Differential scanning calorimetry (DSC):      
 ( Aulton M.E., et al.,2002) 
Any possible drug Disintegrant interaction can be studied by thermal analysis. 
The DSC study was performed on pure drug, drug+ Croscarmellose sodium, 
drug+Crospovidone and drug+ Calcyum Carboxy methyl cellulose. The study was 
carried out using a Shimadzu DSC 60, (Japan). The 2 mg of sample were heated in a 
hermetically sealed aluminium pans in the temperature range of 60˚-180˚C at heating 
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rate of 10ºc /min under nitrogen flow of 30ml/min. The results of DSC analysis were 
presented in figure 8.6 and Table 8.10. 
 
7.1.5.1. Loose Bulk Density (LBD):                                       
 (Lachman L., et al., 1991) 
              An accurately weighed powder blend from each formula was lightly shaken 
to break any agglomerates formed and it was introduced in to a measuring cylinder. 
The volume occupied by the powder was measured which gave bulk volume. The 
loose bulk density (LBD) of powder blends was determined using the following 
formula. 
Loose bulk density = Total weight of powder / Total volume of powder 
7.1.5.2. Tapped bulk density (TBD):                                     
(Lachman  L., et al.,1991) 
               An accurately weighed powder blend from each formula was lightly shaken 
to break any agglomerates formed and it was introduced into a measuring cylinder. 
The measuring cylinder was tapped until no further change in volume was noted 
which gave the tapped volume. The tapped bulk densities (TBD) of powder blends 
were determined using the following formula. 
   Tapped bulk density= Total weight of powder / Total volume of tapped powder 
7.1.5.3. Hausner’s Ratio:                                               
                                                                                                        (Aulton M.E., 2007)         
Hausner’s ratio was determined by following equation,    

’	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  A hausner ratio less than 1.25 indicates good flow while greater than 1.5 indicates 
poor flow. 
7.1.5.4. Carr’s Compressibility Index:  
                             (Aulton M.E., 2007)      
                It is a simple index that can be determined on small quantities of powder. In 
theory, the less compressible a material the more flowable it is. The 
compressibility indices of the powder blends was determined using formula, 
Carr’s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Relationship   between % compressibility and flowability is shown in the table 7.4. 
 
  Table 7.4:  Standards for Carr’s compressibility index 
S. No. Carr’s index Type of flow 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair to passable 
4 23-35 Poor* 
5 33-38 Very poor* 
6 >40 Extremely poor* 
                                      * May be improved by glidant 
7.1.5.5. Angle of repose: 
                                              (Lachman L.,et al.,1991) 
 
The angle of repose was determined by the funnel method. The accurately 
weighed powder was taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured. The angle of repose was calculated using the 
following equation. 
																																						
%&' =
(
)
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Where ‘h’ and ‘r’ are the height and radius respectively of the powder cone 
                            Table 7.5:  Standards for Angle of repose  
S. No. Flowability  Angle of repose (˚) 
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
              * Adding glidant for improving flow 
 
7.1.5.6.   pH:    
                                                                                                                                                                                                                                                          
The pH is the measure of negative logarithm of hydrogen ion concentration of an 
aqueous solution. It is one of the most important factors from which the stand point of 
solubility, stability and physiochemical suitability of a formulation. 
Procedure: 
            Accurately Weighed 1 gm of Tenofovir disoproxil fumarate was dissolved in 
100ml of demineralised water for preparing 1% of solution. The pH value of a 
solution was determined potentiometrically by means of a glass electrode. 
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7.2. METHODOLOGY: 
METHOD OF PREPERATION: 
 Process for the preparation of Tenofovir Disoproxil Fumerate by Wet 
Granulation Method. 
1. Dry Mixing & Sifting 
  Tenofovir Disoproxil Fumerate were loaded into RMG along with 
Microcrystalline cellulose, Croscarmellose sodium Lactose mono hydrate, pre 
gelatinised starch were sifted through #40 and sifted ingredients were  mixed for 10 
minutes at slower speed 
2. Wet Granulation: 
  Purified water was added into RMG while mixing at slower mixer speed. 
Then mixer speed was changed to fast and continued till required consistency of mass 
was obtained. Wet mass has been sifted through #12. 
3. Drying: 
            The dried granules were dried in a tray dryer at 50˚C. 
4. Sifting: 
             Dried granules were sifted through #18.  
5. Prelubrication: 
             Weighed quantity of Croscarmellose sodium and Microcrystalline cellulose. 
Were sifted through #40 and added to dried granules. 
6. Lubrication: 
            Weighed quantity of Magnesium stearate was sifted through #40. and added to 
Pre lubricated blend and mix. 
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7. Compression: 
           The compression was done by using punches of size 16.5×8mm; oval shaped, 
D-tooling, plain surface on upper and lower punch. 
9. Coating:   
         Weighed quantity of Opadry blueII was added to water and stirred for 45 min by 
using mechanical stirrer. Weight gain of the Each tablet is 15mg (2.3%). Equipment 
used was pharma R&D coater. 
Coating parameters: 
Table7.6:  Parameters used in Coating process. 
S.NO PARAMETER COATING DRYING 
1 Inlet temperature 90˚C 90˚C 
2 Pump RPM 2 NA 
3 Air pressure 1.5kg/cm2 NA 
4 Pan RPM 12-14 8 
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Table 7.7:  Formulation of Tenofovir disoproxil fumarate Immediate release Tablets 
INGREDIENTS* 
F1* F2* F3* F4* F5* F6* F7* 
Direct 
compression 
Wet Granulation 
Tenofovir disoporxil 
fumerate 
302 302 302 302 302 302 302 
MCC (pH 101) - - 192 150 110 126 147.9 
MCC (pH 112) 134.5 134.5 - - - - - 
Lactose monohydrate - - 82 128.9 180 147.9 126 
Lactose Anhydrous I47.9 147.9 - - - - - 
Calcium CMC - - 15 - 15 - - 
Povidone K-30 - - - - 20 - - 
Crospovidone - - - 20 - - - 
HPC - - 20 20 - - - 
Pregelatinised starch 20 20 - - - - - 
Croscarmellose sodium 32.5 32.5 - - - 20 20 
Magnesium stearate 6.5 13 8 7 7 6.5 6.5 
Purified Water Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
MCC (pH102) - - 17 21 16 15 15 
Croscarmellose sodium - - - - - 12.5 12.5 
Total 650 650 650 650 650 650 650 
               * All the values were expressed in mg per tablet 
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7.3. EVALUATION PARAMETERS: 
 
 Tablet evaluation in immediate release dosage forms may be divided 
conveniently in to following categories    
7.3.1. Appearance:         
(Lachman L.,et al.,1991; Bankar G.S. and Rhodes C.T.,1996) 
         The tablets were visually observed for capping, chipping, and lamination. 
7.3.2. Physicochemical characteristics:  
 7.3.2.1. Dimension (Thickness and Diameter): 
              (Lachman L., et al.,1991) 
                 The thickness and diameter of tablets were important for uniformity of 
tablet size. The thickness and diameter of the tablets was determined using a Vernier 
caliper. Three tablets from each type of formulation were used and average values 
were calculated. 
7.3.2.2. Tablet Hardness:         
(Lachman L.,et al.,1991; Bankar G.S. and Rhodes C.T., 1996) 
For each formulation, the hardness of 6 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be zero kg/cm2. Then constant 
force was applied by rotating the knob until the tablet fractured. The value at this 
point was noted in kg/cm2.  
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7.3.2.3. Percentage Friability:  
     (Lachman L.,et al.,1991; Bankar G.S. and Rhodes C.T., 1996) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre weighed tablets was placed in Roche friabilator which 
was then operated for 100 revolutions. The tablets were then de dusted and 
reweighed. A loss of less than 1 % in weight is generally considered acceptable. 
Percent friability (% F) was calculated as follows, 
% =
	
		 − 
		
	
		
	×  
 
7.3.2.4. Weight Variation:                                
 (IP, 2007; Lachman L.,et al.,1991 ) 
           To find out weight variation 20 tablets of each formulation were weighed 
individually using an electronic balance, average weight was calculated and 
individual tablet weight was then compared with average value to find the deviation 
in weight.  
Table 7.8:  Specifications of % weight variation allowed in tablets as per IP. 
S. No. Average weight of tablets (mg) Maximum percent 
deviation allowed (%) 
1 130 or less ±10 
2 More than 130 but less than 324 ±7.5 
3 More than 324 ±5 
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   7.3.2.5. In-vitro disintegration test: 
           The test was carried out on 6 tablets using Tablet disintegration tester.  
Distilled water at 37ºC ± 2ºC was used as a disintegration media and the time in 
seconds taken for complete disintegration of the tablet with no palable mass 
remaining in the apparatus was measured.    
Table7.9:  Specifications of Disintegration time 
               Tablet Type Time limit and Specifications 
1. BP 
 Uncoated 
 Coated 
1.film coated 
2.suger coated 
 Gastro resistant, enteric 
 
 Effervescent 
 Soluble 
 Dispersable 
2.USP 
 Uncoated 
 Plain coated 
 Buccal 
 
<15min 
 
<30min 
<60min, repeat in 0.1 N HCl 
>120minin 0.1N HCl 
<60min in pH 6.8 phosphate buffer 
<5min in 200ml Water 
<3min 
<3min 
 
<15min 
<30min 
<4 hours 
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7.3.2.6. In-vitro Dissolution Studies:                                                     
(IP, 2010) 
             Dissolution is considered as one of the most important quality control tests 
performed on pharmaceutical dosage forms and is now developing into a tool for 
predicting bioavailability, and in some cases, replacing clinical studies to determine 
bioequivalence.  
Dissolution:  (By HPLC method) 
 Instrument: 
 HPLC equipped with UV detector and data handling system. 
 Apparatus: 
         Analytical balance, volumetric flasks, Pipettes, 0.45µ membrane filters, 
syringes, dissolution apparatus. 
 Chemicals and reagents: 
• Potassium dihydrogen phosphate-GR grade 
• Ortho-phosphoric acid-HPLC grade 
• Purified water-Milli-Q grade 
• Acetonitrile-HPLC grade 
• Tenofovir disoproxil fumarate working standard 
• Hydrochloric acid. 
 Dissolution  conditions: 
• Medium: 0.1 N HCl 
• Volume: 900 ml 
• Apparatus: USP Type 1 paddle 
• RPM: 50 
• Temperature: 37˚C± 0.5˚C 
• Time interval:45 min 
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 Chromatographic  conditions: 
• Column: stainless steel column 15×4.6mm, packed with Octa decyl 
silane bonded to porous silica(5µm) 
• Flowrate:1.0 ml/min 
• Wavelength:260nm 
• Column temperature:30˚c 
• Injection volume:10µl 
• Run time: 12 min. 
 Preparations: 
  1. Dissolution medium: Used 0.1 N HCl (8.5 ml in 1000 ml of purified water) as 
dissolution medium. 
  2. Buffer preparation:  Accurately weighed and transferred about 4.4 gm of 
Potassium di hydrogen phosphate into 1000 ml of purified water. Adjusted the pH of 
solution to 3.0 with dilute Ortho-phosphoric acid. 
  3. Mobile phase–A preparation: Prepared a filtered and degassed mixture of buffer 
and Acetonitrile in ratio of 70:30 v/v respectively. 
 4. Mobile phase–B preparation: Prepared a filtered and degassed Acetonitrile –
HPLC grade. 
 5. Tenofovir Disoproxil fumarate standard preparation:  
                Accurately weighed and transferred about 33.3mg of Tenofovir working 
standard into a 100 ml volumetric flask. Added about 60ml of diluents and sonicated  
to dissolve. Cooled the solution to room temperature and diluted to volume with 
dissolution medium. 
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6. Sample preparation: 
            Placed one tablet in each of six dissolution flasks containing 900ml of 
dissolution medium, previously maintained at 37˚C ± 0.5˚C,taking care to exclude air 
bubbles from the surface of each dosage unit and immediately operated the apparatus 
for 30min. 
           After completion of specified time interval ,withdrew a portion of solution 
from zone midway between the surface of dissolution medium and top of rotating 
blade, not less than 1 cm from vessel wall and filter through 0.45 µ membrane filter. 
Percentage content of Tenofovir disoproxil fumarate 
                          = TA / SA *   SW / 100 *     900/1 * P/100 * 100/ LA   
Where  
TA = Peak area response due to Tenofovir disoproxil fumarate from sample 
preparation 
  SA= Peak area response due to Tenofovir disoproxil fumarate from standard 
preparation 
 SW=Weight of Tenofovir disoproxil fumarate working standard taken in mg. 
P=Purity of Tenofovir disoproxil fumarate working standard taken on its basis. 
LA=Labelled amount of Tenofovir disoproxil fumarate. 
7.3.2.7. Assay:                                                                                           (IP, 2010) 
               Although the specifications for assay results differ from product to product, 
generally the expected range for individual active ingredient is to be within 95%–
105% of the labelled amount.  
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 Instrument: 
                HPLC equipped with UV detector and data handling system. 
 Apparatus: 
               Analytical balance, volumetric flasks, Pipettes, 0.45µ membrane filters. 
 Chemicals and reagents: 
• Potassium di hydrogen phosphate-GR grade 
• Ortho-phosphoric acid-HPLC grade 
• Purified water-Milli-Q grade 
• Acetonitrile-HPLC grade 
• Tenofovir disoproxil fumarate working standard 
 Chromatographic conditions: 
• Column: a stainless steel column 15×4.6mm, packed with Octadecyl 
silane bonded to porous silica(5µm) 
• Flowrate:1.0 ml/min  
• Wavelength:260 nm 
• Column temperature:30˚C 
• Injection volume:10µl 
• Run time: 12 min. 
Preparations: 
1. Buffer preparation: Accurately weighed and transferred about 4.4 gm of 
Potassium dihydrogen phosphate into 1000 ml of purified water. Adjusted the pH of 
solution to 3.0 with dilute Ortho-phosphoric acid. 
2. Mobile phase –A preparation:  Prepared a filtered and degassed mixture of buffer 
and Acetonitrile in ratio of 70:30 v/v respectively. 
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3. Mobile phase –B preparation: Prepared a filtered and degassed Acetonitrile –
HPLC grade. 
 4. Diluent preparation: Mixed the buffer and Acetonitrile in ratio of 60:40 v/v 
respectively. 
5. Tenofovir disoproxil fumarate standard preparation: Accurately weighed and 
transferred about 30mg of Tenofovir working standard into a 250 ml volumetric flask. 
And added about 180ml of diluents and sonicated to dissolve. Cooled the solution to 
room temperature and diluted to volume with diluents (0.12 mg/ml of 
Tenofovir).diluted 5.0 ml of above solution to 20ml with Mobile phase. 
6. Sample preparation: Weighed and finely powdered not less than 20 tablets. 
Transferred an accurately weighed portion of the powder equivalent to 300 mg of 
Tenofovir, dissolved in 100 ml of the solvent mixture and filtered. Diluted 5ml of the 
filtrate to 50.0 ml with the mobile phase. 
System suitability: 
                  Chromatograph the standard preparation (six replicate injections), measure 
the peak area response for the analyte peak and evaluate the system suitability 
parameters as directed. 
 Procedure: 
                  Separately injected equal volumes (about 20µl) of the water as blank, 
standard preparation and sample preparation into Column and recorded the 
chromatograms and measured the peak area response for analyte peak. Calculated the 
percentage content of  Tenofovir Disoproxil fumarate tablets taken by formula. 
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 Percentage content of Tenofovir disoproxil fumarate 
= TA / SA   *   SW / 250 *   2/20   *   250/TW   * 100/1 * P/100 * AVG WT/ LA * 
100 
Where, 
TA   = Peak area response due to   Tenofovir disoproxil fumarate from sample 
preparation. 
SA= Peak area response due to Tenofovir disoproxil fumarate from standard 
preparation. 
SW=Weight of   Tenofovir disoproxil fumarate   working standard taken in mg. 
TW=Weight of sample taken in mg. 
P=Purity of   Tenofovir disoproxil fumarate   working standard taken on its basis. 
AVG WT=Average weight of tablets. 
LA=Labelled amount of   Tenofovir disoproxil fumarate. 
7.4. STABILITY STUDY:                    
  (Manavalan .R and  Ramasamy S., 2007) 
 Introduction: 
                 In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date of 
manufacture and the packaging of the formulation, until its chemical or biological 
activity is not less than a predetermined level of labelled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
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 Objective of the study: 
                  The purpose of stability testing is to provide evidence on how the quality 
of a drug substance or drug product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products (QIA) 
describes the stability test requirements for drug registration application in the 
European Union, Japan and the States of America. 
ICH specifies the length of study and storage conditions  
 Study specifications: 
        Table7.10:  ICH Specifications for  Accelerated stability testing 
S.NO. STUDY STORAGE CONDITION 
MINIMUM 
TIME PERIOD 
1. Long term 
25ºC± 2ºC/60 %RH± 5%RH 
(or) 30C±2ºC/ 65%RH±5%RH 
12 months 
2. Intermediate 30ºC±2ºC/65%RH±5%RH 6months 
3. Accelerated 40ºC ±2ºC / 75% RH ±5 % RH 6months 
 
             In present study, the selected formulation F6 exposed  upto 3 months stability 
studies at accelerated condition (40˚ C ±2˚C at 75% RH±5%RH) to find out the effect 
of aging on hardness, Disintegration time , drug content and In-Vitro drug released.  
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 Procedure: 
                      Stability studies were carried out at accelerated condition (40˚ C ±2˚ C 
at 75% RH ±5%RH) for the optimized formulation F6. The tablets were stored at 40˚ 
C ±20˚C at 75% RH ±5%RH for accelerated temperature in closed high density 
polyethylene bottles for 3 months. The samples were withdrawn after Pre determined 
Period of 1 month, 2 month and 3 month. The samples were analyzed for its hardness, 
Disintegration time, drug content and In-Vitro drug released.  
7.5. INNOVATOR PRODUCT CHARACTERISATION: 
Brand name:  VIREAD 
Strength: 300mg 
Excipients: Each Tablet Contains, 
           Tenofovir disoproxil fumarate, Croscarmellose sodium, lactosemonohydrate, 
Magnesium stearate, Microcrystalline cellulose, Pregelatinised starch. And Tablets 
were coated with Opadry blueII 
Discription:  
            The tablets are almond shaped, light blue coated, and debossed with 
”GILEAD” and” 4331”on one side of the tablet and with “300”on the other side. 
Size: 17.5mm 
Width: 8.30mm 
Hardness: 6.5±0.17kg/cm2 
Disintegration time: 5.25±0.20min 
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In-vitro Dissolution studies of INNOVATOR product: 
Table7.11: In-Vitro drug released data of Innovator product 
 
S.NO Dissolution medium Time(min) %Drug released 
1  
 
0.1 N HCl 
0 0 
2 5 39.6±0.26 
3 10 65.8±0.20 
4 15 73.5±0.38 
5 30 90.6±0.45 
6 45 99.8±0.27 
*All values are expressed as mean ±S.D., n=3. 
 
                   Figure7.2: Plot of In- Vitro drug released profile of Innovator product 
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8.1. PREFORMULATION PARAMETERS: 
8.1.1. Identification of drug:   
8.1.1.1. Identification by HPLC Chromatographic method: 
 
 
 
 
 
 
Figure 8.1:  HPLC Chromatogram of Assay of Tenofovir disoproxil fumarate 
(Standard)  
 
 
 
 
 
 
 
   Figure 8.2: HPLC Chromatogram of Assay of Tenofovir Disoproxil fumarate       
(Sample) 
8. RESULTS AND DISCUSSION 
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         In the assay, as the principal peak in the chromatogram obtained with the test 
solution matched to the peak in the Chromatogram with the reference solution. Hence 
the Sample was confirmed as Tenofovir disoroxil fumarate. 
 
8.1.1.2. Melting point: 
Melting point values of Tenofovir disoproxil fumarate sample was found to be 
in range of 114.8˚C to 118.5˚C. The reported melting point for Tenofovir disoproxil 
fumarate was 115.2˚C. Hence, experimental values were in good agreement with 
official values. 
8.1.2. Physicochemical parameters of drug: 
8.1.2.1. Organoleptic properties: 
Odour:  Odourless  
Colour:  White to off white 
Nature: Crystalline powder.  
8.1.2.2. Solubility study: 
 Table 8.1:  Solubility of Tenofovir disoproxil fumarate in various solvents 
 
 
 
S.NO Name of solvent Solubility 
1 Distilled water Sparingly Soluble 
3 0.1N HCl Soluble 
4 Methanol Freely Soluble 
5 Di methyl formamide Soluble 
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8.1.2.3. Loss on drying  
The percentage loss on drying after 3 hours was found to be as follows 
 
Table 8.2: Percentage loss on drying of Tenofovir disoproxil fumarate 
*All values are expressed as mean ±S.D., n=3. 
                Sample passes test for loss on drying as per the limit specified in IP, 2010 
(N.M.T.3.5%) 
8.1.3. Analytical methods: 
8.1.3.1. Preparation of standard graph of Tenofovir disoproxil fumarate: 
 The drug obeys Beer- Lambert’s law in the range of 12-60µg /ml. 
 
Table 8.3:  Data for Standard graph of Tenofovir disoproxil fumarate in 0.1N HCl 
 
S. No. Concentration Area of the peak 
1 12 1281809 
2 24 2563618 
3 36 3845467 
4 48 5127276 
5 60 6409124 
 
 
Sr. No. Percentage  LOD Average percentage LOD 
1 2.6  
2.76±0.152 
 
2 2.8 
3 2.9 
Tenofovir Disoproxil fumarate immediate release tablets Results & Discussion 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 106 
 
 
 
 
Figure 8.3:  Standard graph of Tenofovir disoproxil fumarate in 0.1N HCl 
  
Table 8.4: Data for Standard graph Parameters of Tenofovir disoproxil fumarate 
  
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9997 
2 Slope  96182.78 
3 Intercept 639973.4 
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8.1.3.3. Percentage purity of drug 
The percentage purity of drug was calculated by using HPLC method  
                         Table 8.5:  Percentage purity of Tenofovir disoproxil fumarate 
*All values are expressed as mean ±S.D., n=3. 
 The reported % purity for Tenofovir disoproxil Fumarate in IP 2010 is 97-102% 
8.1.4. Determination of compatibility for drug with excipients: 
8.1.4.1. By HPLC Chromatographic method: 
 
Figure 8.4: HPLC Chromatogram of Tenofovir disoproxil fumarate Impurities 
(Initial) 
S. No. Percentage purity (%) Average percentage purity 
(%) 
1 100.82  
100.97±0.12 2 101.02 
3 101.06 
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Table 8.6: Impurities present in  Tenofovir disoproxil fumarate (Initial) 
S.NO Peak Name RT Area %Area 
1 Adinine 7.791 3652 0.02 
2 Tenofovir imp 10.574 8676 0.04 
3 Monoester imp 24.285 137692 0.68 
4 Ethyl imp-1 34.587 4668 0.02 
5 Isopropyl imp 41.388 36081 0.18 
6 Carbonyl imp 76.418 1751 0.01 
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Figure 8.5: HPLC Chromatogram of Tenofovir disoproxil fumarate Impurities 
(3months) 
 
Table 8.7: Impurities present in Tenofovir disoproxil fumarate after 3 months. 
  
S.NO Peak Name RT Area %Area 
1 Adenine 7.231 2690 0.01 
2 Tenofovir 9.722 14581 0.04 
3 Monoester 93.986 302855 0.88 
4 Ethyl 33.442 7472 0.02 
5 Isopropyl 39.531 62791 0.18 
6 Carbonyl 73.350 1239 0.00 
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Table 8.8: Impurities present in the Tenofovir disoproxil fumarate during 
compatibility study (Initial) 
 
Initial analysis: (40˚C±2˚C/75%RH±5%RH)         
Name Of Drug/ 
Excipient Ratio 
Related Substances 
Imp-A Imp-B Imp-C Imp-D Imp-E 
Total 
Impurities 
TDF - 0.15 0.15 0.2 0.08 0.15 
0.5 
 
TDF +Pregelatinised 
Starch 1500 
 
1:0.1 0.025 0.049 0.0053 0.048 0.033 0.05 
TDF+ Lactose 
monohydrate 
1:1 0.004 0.09 0.003 0.08 0.09 0.04 
TDF +  Calcium CMC 
 
1:1 0.004 0.08 0.006 0.07 0.003 0.03 
TDF + Croscarmellose 
sodium 
 
1:0.25 0.004 0.06 0.061 0.002 0.002 0.033 
TDF+ Crospovidone 
 
1:0.25 0.043 0.07 0.004 0.05 0.0074 0.037 
TDF + Opadry Blue II 
 
1: 0.1 0.07 0.09 0.067 0.027 0.065 0.005 
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Table 8.9: Impurities present in Tenofovir disoproxil fumarate during compatibility 
study (3 months) 
3 Months analysis: (40˚C±2˚C/75%RH±5%RH) 
Name Of Drug/ 
Excipient 
Ratio Related Substances 
Imp-A Imp-B Imp-C Imp-D Imp-E Total 
Impurities 
 
TDF 
- 0.035 0.065 0.02 0.068 0.105 0.45 
 
TDF+Pregelatinised 
Starch 1500 
1:0.1 0.05 0.059 0.03 0.08 0.073 0.05 
TDF + Lactose 
monohydrate 
1:1 0.04 0.029 0.033 0.08 0.09 0.034 
TDF +  Calcium 
CMC 
1:1 0.024 0.038 0.066 0.071 0.003 0.033 
TDF + 
Croscarmellose 
sodium 
1:0.25 0.005 0.0536 0.021 0.022 0.024 0.053 
TDF + 
Crospovidone 
1:0.25 0.03 0.07 0.04 0.05 0.074 0.03 
TDF + 
Opadry Blue II 
1: 0.1 0.07 0.09 0.07 0.027 0.065 0.035 
Where,                    
                                  ImpA- Tenofovir impurity 
                                  Imp-B-. Adenine impurity 
                                  Imp-C- Monoester  impurity 
                                  Imp-D- Ethyl  impurity,  Imp-E- Carbonyl impurity 
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8.1.4.2. By DSC thermal analysis:  
The compatibility and interactions between drugs and disintegrant were 
checked using DSC; results obtained were shown in figure 8.6 
 
 
 
 
 
 
 
 
 
TDF+Croscarmellose sodium 
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                                                      TDF+Crospovidone 
 
 
 
 
 
 
 
 
                                     TDF+Calcium Carboxy methyl cellulose 
 
 Figure8.6: DSC thermograms of TDF , TDF with Croscarmellose  sodium, TDF with 
Crospovidone, TDF with Calcium carboxy methyl cellulose.  
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Table 8.10: Data of DSC thermogram parameters 
S.NO DSC thermogram of 
Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
End set 
temperature 
(°C) 
1 D4T 114.88 115.12 117.06 
2 
D4T+croscarmellose 
sodium 
114.25 115.08 117.35 
3 D4T+Crospovidone 114.26 115.06 117.33 
4 D4T+ Calcium CMC 114.16 115.08 117.25 
 
According to figure 8.6 and table 8.10, DSC thermogram showed that there 
was no major difference in onset temperature, end set temperature and peak 
temperature when compared with pure drug’s thermogram. No interaction was found 
between drug and disintegrants. Therefore it could indicate that there was no 
incompatibility between drug and different polymer. 
 
8.1.5. Determination of physical Characteristics of API: 
Table 8.11:  Physical Characteristics of API 
S. No. Parameters Results 
1 Bulk density(gm/ml) 0.431±0.00 
      2 Tapped  density(gm/ml) 0.657±0.01 
     3 Compressibility index(%) 34.483±0.14 
     4 Hausner’s ratio 1.524±0.01 
      5. Angle of repose(˚) 24.62 
                                   *All values are expressed as mean ±S.D.,n=3. 
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                    Table 8.12: Particle Size Analysis of API by Sieve Analysis  
S. No ASTM  
 
Empty 
Mesh wt. 
(A) g.  
Mesh + 
Powder 
wt (B) g. 
(B-A)  % Retained  
Cumulative 
%  
1 18 356.4 356.4 0 0 0 
2 35 367.7 367.9 0.2 1 1 
3 60 393.9 401.3 7.4 37 38 
4 80 385.7 391 5.3 26.5 64.5 
5 100 335.7 337 1.3 6.5 71 
6 140 325.7 330.7 5 25 96 
7 200 319.1 319.6 0.5 2.5 98.5 
8 Collect
or  
533.3 533.4 0.1 0.5 99 
                          
                            Weight of powder taken -20 gms,  
                                                           Time - 5 mints. 
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8.1.6. Determination of Physical Characteristics of lubricated blend: 
                    Table 8.13:  Physical characteristics of lubricated blend 
 
FORMUL
ATION 
CODE 
 
 
BULK 
DENSITY* 
 (gm/ml) 
 
 
TAPPED 
DENSITY* 
(gm/ml) 
 
 
COMPRESSI
BILITY 
INDEX* 
(%) 
 
HAUSNER’S 
RATIO* 
 
ANGLE OF 
REPOSE* 
(˚) 
F1 0.441±0.00 0.625±0.00 29.41±0.03 1.417±0.01 28.26±0.15 
F2 0.455±0.00 0.625±0.01 27.27±0.05 1.375±0.00 26.34±0.14 
F3 0.449±0.01 0.598±0.00 24.47±0.04 1.33±0.01 25.63±0.06 
F4 0.431±0.01 0.577±0.01 25.30±0.03 1.476±0.02 25.31±0.24 
F5 0.462±0.01 0.619±0.02 24.56±0.02 1.308±0.00 24.61±0.28 
F6 0.478±0.00 0.619±0.01 22.77±0.04 1.29±0.01 23.59±0.17 
F7 0.441±0.01 0.577±0.01 23.53±0.04 1.38±0.01 23.62±0.15 
 *All values are expressed as mean ±S.D., n=3. 
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8.1.7. Determination of Physical Characteristics of dried granules: 
                     Table 8.14: Physical Characteristics of dried granules 
 
 
FORMUL
ATION 
CODE 
 
 
BULK 
DENSITY* 
 (gm/ml) 
 
 
TAPPED 
DENSITY* 
(gm/ml) 
 
 
COMPRESSI
BILITY 
INDEX* 
(%) 
 
HAUSNER’S 
RATIO* 
 
ANGLE OF 
REPOSE* 
(˚) 
F3 0.420±0.01 0.592±0.00 27.81±0.04 1.40±0.01 25.63±0.06 
F4 0.462±0.01 0.577±0.01 24.83±0.03 1.31±0.02 25.31±0.24 
F5 0.419±0.01 0.559±0.02 25.00±0.02 1.33±0.00 24.61±0.28 
F6 0.449±0.00 0.568±0.01 21.89±0.04 1.27±0.01 23.59±0.17 
F7 0.426±0.01 0.598±0.01 22.74±0.04 1.40±0.01 23.62±0.15 
                           *All values are expressed as mean ±S.D., n=3. 
 
8.1.8. pH:   
    pH of Tenofovir disoproxil fumarate:3.30 
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8.2. EVALUATION OF TABLETS: 
8.2.1. Appearance: 
            The tablets were observed visually, they did not showed any defects such as 
capping, chipping and lamination. 
              Colour: Blue coloured 
              Shape: Oval shaped 
8.2.2. Physicochemical characteristics: 
             The physical characteristics of Tenofovir disoproxil fumarate (F1 to F7) such 
as thickness, diameter, hardness, friability, weight variation and drug content were 
determined and results of the formulations F1 to F7 found to be within the limits 
specified in official books. 
Table 8.15: Physicochemical characterisation of Tenofovir disoproxil fumarate 
Immediate release tablets before coating 
CODE Thickness* 
(mm) 
Hardness* 
(kg/cm2) 
Friability* 
% 
Weight 
variation* 
Disintegration 
time(min)* 
F1 5.71±0.01 7.3±0.15 0.12±0.01 0.16±0.04 5.25±0.18 
F2 5.71±0.01 7.1±0.14 0.16±0.04 0.22±0.017 5.22±0.24 
F3 5.77±0.02 5.5±0.22 0.14±0.02 0.18±0.02 5.14±0.15 
F4 5.67±0.01 6.5±0.17 0.09±0.03 0.20±0.05 5.20±0.12 
F5 5.74±0.04 5.6±0.12 0.18±0.02 0.19±0.04 5.02±0.15 
F6 5.74±0.02 6.4±0.15 0.09±0.03 0.18±0.06 4.45±0.05 
F7 5.75±0.04 6.3±0.12 0.15±0.02 0.20±0.04 5.01±0.08 
*All values are expressed as mean ±S.D., n=3. 
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Table 8.16: Physicochemical characterisation of Tenofovir disoproxil fumarate 
immediate release tablets after coating 
CODE Thickness* 
(mm) 
Hardness* 
(kg/cm2) 
Friability* 
% 
Weight** 
variation 
Drug 
content(%w/w)* 
F1 5.98±0.16 7.5±0.15 0.09±0.01 0.14±0.02 98.75±0.47 
F2 5.98±0.15 7.2±0.14 0.10±0.04 0.22±0.01 98.90±0.43 
F3 6.12±0.14 5.6±0.22 0.09±0.02 0.29±0.04 99.75±0.40 
F4 6.08±0.09 6.8±0.17 0.07±0.03 0.32±0.017 100.1±0.42 
F5 6.04±0.10 5.8±0.12 0.12±0.02 0.35±0.06 99.89±0.47 
F6 6.12±0.15 6.5±0.15 0.08±0.03 0.25±0.02 101.2±0.35 
F7 6.08±0.08 6.6±0.12 0.09±0.02 0.24±0.03 100.8±0.38 
*All values are expressed as mean ±S.D., n=3,**n=20. 
 
8.2.2.1. Dimension (Thickness and Diameter): 
Thickness and diameter specifications may be set on an individual product 
basis. There were no marked variations in the thickness and diameter of tablets within 
each formulation indicating uniform behaviour of granules throughout the 
compression process. The size (length) of the tablets of all formulations were found to 
be 17.33 to 17.36mm and width ranged between 8.26to8.28mm 
8.2.2.2. Tablet Hardness: 
A difference in tablet hardness reflects difference in tablet density and 
porosity. Which in turn are supposed to result in different release pattern of the drug 
by affecting the rate of penetration of dissolution fluid at the surface of the tablet and 
formation of gel barrier. The hardness of tablets was found to be in the range of 6.4 
kg/cm2 to 7.3 kg/cm2. This indicates good tablet strength.  
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8.2.2.3. Percentage Friability: 
    Percentage friability of all the formulations was found between 0.35 to 0.46 %. 
This indicated good handling property of the prepared tablet. 
8.2.2.4. Weight Variation: 
A tablet was designed to contain a specific amount of drug. When the average 
mass of the tablet was and 300 mg the pharmacopoieal limit for percentage deviation 
was ±5%. The percentage deviation from average tablet weight for all the tablet was 
found to be within the specified limits and hence all formulations complied with the 
test for weight variation according to the pharmacopoieal specifications IP 2007. 
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8.2.5. In-vitro disintegration studies:
Table 8.17: Comparison of
formulations (F1toF7) 
INNOVATOR
                               *All values are expressed as mean ±S.D., n=3.
Figure 8.7: Comparison of 
formulations (F1 toF7)
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 disintegration time of Tenofovir disoproxil fumarate 
with Innovator after coating 
 
CODE Disintegration time(min) 
F1 7.28±0.12 
F2 7.20±0.14 
F3 6.28±0.18 
F4 7.04±0.28 
F5 6.24±0.18 
F6 5.23±0.16 
F7 5.34±0.23 
 
5.25±0.25 
 
disintegration time of Tenofovir disoproxil fumarate
 with Innovator after coating. 
F3 F4 F5 F6
Formulation code
 
Page 121 
 
 
 
F7 Innovator
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8.2.5. In-Vitro Drug released Studies: 
 
Table 8.18:  In-Vitro drug released data of formulation F1 
S.N0 Dissolution  
Medium 
Time (min) DR*  
(%) 
1 
 
 
0.1N HCl 
0 0.00 
2 5 30.4±0.07 
3 10 60.3±0.30 
4 15 73.5±0.52 
5 30 89.7±0.21 
6 45 98.5±0.56 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.8:  Plot of In-Vitro drug released profile of formulation F1 
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                 Table 8.19: In-Vitro drug released data of formulation F2 
S.NO Dissolution 
Medium 
Time (min) DR* 
(%) 
             1 
 
 
          0.1N HCl 
0 0.00 
2 5 33.4±0.12 
3 10 66.3±0.67 
4 15 78.8±0.49 
5 30 90.4±0.54 
6 45 98.9±0.49 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
 
Figure 8.9:  Plot of In-Vitro drug released profile of formulation F2 
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               Table 8.20: In-Vitro drug released data of formulation F3 
S.NO Dissolution 
medium  
Time (min) DR* 
(%) 
1 
 
    
      0.1N HCl 
0 0.00 
2 5 30.6±0.32 
3 10 53.9±0.41 
4 15 78.1±0.50 
5 30 90.8±1.27 
6 45 99.7±0.46 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
                   Figure 8.10:  Plot of In-Vitro drug released profile of formulation F3 
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             Table 8.21: In-Vitro drug released data of formulation F4 
S.NO Dissolution  
medium 
Time (min) DR*  
(%) 
1 
 
 
0.1N HCl 
0 0.00 
2 5 32.9±0.46 
3 10 64.2±0.44 
4 15 74.5±0.28 
5 30 89.9±0.48 
6 45 98.8±0.10 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.11: Plot of In-Vitro drug released profile of formulation F4 
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                    Table 8.22: In-Vitro drug released data of formulation F5 
S.NO 
Dissolution 
medium 
Time (min) DR* (%) 
1 
       0.1N HCl 
0 0.00 
2 5 34.5±0.40 
3 10 63.7±0.55 
4 15 75.9±0.36 
5 30 91.2±0.43 
6 45 99.3±0.82 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
 
Figure 8.12: Plot of In-Vitro drug released profile of formulation F5 
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                     Table 8.23: In-Vitro drug released data of formulation F6 
S.NO Dissolution medium Time (min) DR* 
(%) 
1 
 
 
0.1N HCl 
 
 
0 0.00 
2 5 38.7±0.79 
3 10 67.2±0.23 
4 15 76.5±0.33 
5 30 92.5±0.62 
6 45 100.2±0.17 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
               Figure 8.1 Plot of In-Vitro drug released profile of formulation F6 
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Table 8.24: In-Vitro drug released data of formulation F7 
S.NO Dissolution 
medium 
Time (min) DR* 
(%) 
1 
 
 
0.1NHCl 
0 0.00 
2 5 34.5±0.06 
3 10 62.2±0.27 
4 15 74.8±0.55 
5 30 91.5±0.38 
6 45 99.8±0.30 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
 
Figure 8.14: Plot of In-Vitro drug released profile of formulation F7 
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Table 8.25: Comprehensive In-Vitro drug released data of all formulations (F1-
F7)with innovator product. 
Time 
(min) 
Formulation code INNOVATOR 
PRODUCT F1 F2 F3 F4 F5 F6 F7 
0 0 0 0 0 0 0 
 
0 0 
5 30.4 33.2 
 
30.6 
 
32.9 
 
34.5 
 
38.7 
 
34.5 
 
39.6 
 
10 50.3 
 
56.3 
 
53.9 
 
64.2 
 
63.7 67.2 
 
62.2 
 
65.8 
 
15 73.5 
 
74.6 
 
78.1 
 
74.5 
 
75.9 
 
76.5 
 
74.8 
 
73.5 
30 88.4 89.9 
 
90.8 
 
89.4 
 
91.2 
 
92.5 
 
91.8 
 
90.6 
 
45 98.5 
 
98.9 
 
99.7 
 
98.8 
 
99.4 
 
100.2 
 
98.9 
 
99.8 
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   Figure 8.15: Comparison Plot of In-Vitro Drug released profile of formulations 
 (F1 toF7) with Innovator. 
   
 Figure 8.16: Comparison Plot of In-Vitro drug released profile of direct compression 
formulations (F1&F2) with Innovator 
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Figure 8.17: Comparison Plot of In-Vitro drug released profile of Calcium carboxy 
methyl cellulose containing formulations (F3&F5) with Innovator 
 
Figure 8.18: Comparison Plot of In-Vitro drug released profile of Crospovidone 
containing formulation (F4) with Innovator.        
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Figure8.19: Comparison Plot of In-Vitro drug released of Croscarmellose containing  
Formulations (F6&F7) with Innovator. 
               According to In-Vitro drug released profile of formulations F1&F2 prepared 
by direct compression method were found to be 98.5% &98.9% drug released 
respectively.  The drug released data of formulations F3&F5 containing Calcium 
carboxy methyl cellulose as disintegrant were found to be 99.7%&99.4% drug 
released respectively, the drug released data of formulation F4 containing 
Crospovidone as  disintegrant were found to be 98.8% drug released and the drug 
released data of Formulations F6&F7 containing Croscarmellose sodium as 
disintergrant were found to be 100.2%&99.8% drug released respectively. Based on 
above drug released profiles, the formulation F6 was showed a highest In-Vitro 
released profile among the all formulations. So the formulation F6 was selected for 
further studies 
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 Table 8.26: Comparison of time of drug released values of t25, t50 and t90 for 
Tenofovir disoproxil fumarate tablet formulations (F1 to F7) with innovator. 
Formulation code Time of %Drug released(min) 
t25 t50 t90 
F1 3.5 8.0 29.0 
F2 3.0 7.0 27.0 
F3 3.5 7.5 27.5 
F4 3.0 6.5 28.5 
F5 2.5 6.0 28.0 
F6 3.0 6.5 26.0 
F7 3.0 6.5 27.5 
INNOVATOR 3.0 6.0 26.5 
 
 
Figure 8.20: Comparitive histogram of time of drug released values of t25, t50, t90 for 
Tenofovir disoproxil fumarate  formulations (F1-F7) with Innovator . 
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8.3. STABILITY STUDY 
  The best formulation F6 was exposed to accelerated stability conditions and 
subjected to various evaluation parameters, and  results were shown in table 8.27.  
 
          
 
             Table 8.27:  Stability study data of optimised formulation (F6)  
Parameter Initials 1 Month 2 Month 3 Month 
Description 
 
Bluecoloured,oval 
shaped,coated 
tablet 
Complies Complies Complies 
Average wt(mg)   666.7±0.05 666.6±0.08 667.8±0.02 668.2±0.07 
Assay(%w/w) 101.2±1.25 100.8±1.38 100.2±1.02 100.06±0.98 
Hardness(kg/cm2) 7.5±0.5 7.0±1.0 6.75±0.5 6.5±1.5 
Disintegration 
time(min) 
5.25±0.20 5.23±0.34 5.21±0.26 5.18±0.38 
                  *All values are expressed as mean ±S.D., n=3. 
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Table 8.28: Comparison of In-Vitro drug released data of Optimised formulation( F6) 
1st,2nd and 3rd month 
Time (min) % drug released 
1stmonth 2ndmonth 3rdmonth 
0 0 0 0 
5 38.5 38.2 38.1 
10 66.8 65.9 65.3 
15 74.5 73.9 73.1 
30 92.7 92.1 91.2 
45 100.2 99.7 99.4 
 
 
Figure 8.21: Comparison plot of In-Vitro drug released profile of optimised 
formulation (F6) after 1st, 2nd and 3rd month. 
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              From the stability studies, no major difference was found between evaluated 
parameters before and after stability studies and all are in acceptable limits. The 
tablets showed satisfactory physical stability at 40˚C±2˚C/75 % RH±5%RH.
  
 
SUMMARY 
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              A Successful immediate release drug delivery system was prepared with 
immediate release mechanism that gives immediate on set of action and compared 
with that of marketed product. 
 Tenofovir disoproxil fumarate possessed longer half life; hence it was a good 
candidate for Immediate release drug delivery system. The identification of drug was 
carried out by HPLC and Melting point. The physicochemical parameters such as 
appearance, solubility study and loss on drying were performed by suitable methods. 
The analytical profile of drug was evaluated for   development of standard curve and 
percentage purity of drug. Compatibility of drug and excipient mixture was done by 
performing HPLC and DSC study. The powder blend was prepared by blending the 
various ingredients in mortar and pestle for 20 min and evaluated for bulk density, 
tapped density, carr’s index, hausner’s ratio and angle of repose.  
         Immediate release tablets of Tenofovir disoproxil fumarate was obtained by wet 
granulation method for all the formulations F1 to F7. Formulations prepared 
composed of Crospovidone, Croscarmellose sodium, and Calcium carboxy methyl 
cellulose as disintegrants with other excipients like Lactose as diluent, HPC, 
Pregelatinised starch,PovidoneK-30 as a binder, microcrystalline cellulose pH 102 as 
a Filler, magnesium stearate as a lubricant. The all tablet formulations were evaluated 
for the appearance, dimension, hardness, percentage friability, weight variation, drug 
content, and In-Vitro drug released profile. On the performance with respect to 
disintegration time and the drug release characteristics, the formulation F6 was 
9. SUMMARY AND CONCLUSION 
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selected as the best formulation as compared with innovator product. This formulation 
showed  Immediate released rate,  that showed 90% release within 30 minutes. 
             The study has revealed that by interchanging the disintegrant, drug released 
rate of drug was improved and results confirmed that the drug released rate from 
tablets depends on type of disintegrant. 
 According to stability study it was found that there was no significant change 
in hardness, drug content, disintegration time and In-Vitro dissolution of optimized 
formulation F6. 
  It may be concluded that the Immediate release tablets of Tenofovir 
disoproxil fumarate was feasible and may be manufactured with reproducible 
characteristics with the aid of Croscarmellose sodium as disintegrant. From the above 
all trials we conclude that formulation F6 obeys all the results within the Standard 
limits as that of innovator product.  However it needs further in depth In Vivo release 
studies on suitable animal models with statistical clinical data for a dependable and 
successful pharmaceutical marketing formulation. 
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                 In the field of Immediate release, there are many obstacles that need to be 
overcome in order to be able to claim true immediate release. Considering the 
advantages for improved delivery of drugs further clinical studies were needed to 
access the utility of this system for patients suffering from HIV. 
     This dosage forms holds promise for further systems. In-Vitro and In-Vivo 
correlation (IVIVC) will serve as a means of modelling the human organism and of 
gaining a better understanding of drug absorption and its dependence on In-Vitro 
release process.  
    Finally while the increasing the drug release profile there by immediate on 
set of action has been a major aim of pharmaceutical research and development in the 
past two decades, the increasing of Onset of action by Immediate release profiles.  
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